

CURRICULUM VITAE

Name: Socrates E. PAPAPOULOS

Date of birth: 17th March 1947

Place of birth: Athens, Greece

Nationality: Greek/Dutch

Marital status: Married to Dr. V. Papaioannou (pathologist) with two children

Address: The Leiden Center for Bone Quality
Leiden University Medical Center
Albinusdreef 2
2333 ZA Leiden
The Netherlands
Tel. 31-(0)71-5262490; fax 31-(0)-71-5248136
e-mail s.e.papapoulos@lumc.nl

Education: Athens College (Greek-American secondary school)
Medical School, University of Athens (1964-1970)

Qualifications: 1970 (June) - Diploma of Medicine, Medical School,
University of Athens, Greece
1974 (December) - Specialty of Internal Medicine,
Athens, Greece
1976 (December) - Doctor of Medicine, Medical School,
University of Athens, Greece. Dissertation: The diagnostic
approach to disorders of parathyroid function (Cum Laude)
1979 (February) - Subspecialty of Endocrinology, Athens, Greece.

**Registration in
The Netherlands:** 1984 (November) Internal Medicine (Endocrinology)

**Appointments
since qualification:** - 1971 (June) - 1974 (June), Assistant and Instructor, 1st Department
of Internal Medicine, Medical School, University of Athens,
Vasileus Pavlos Hospital, Athens (Head, Professor P. Fessas).

- 1974 (August) - 1975 (August), Senior Assistant and
Instructor, Department of Medicine, State Hospital for
Infectious Diseases, Athens (Head, Ass. Professor
P. Kontoyiannis).

- 1975 (September) - 1980 (June), Research Fellow, Clinical Research Assistant (Clinical Lecturer since 1978) in Endocrinology and Metabolism, Department of Medicine, The Middlesex Hospital Medical School, University of London, U.K. (Professor JLH O'Riordan).

- 1980 (September) - 1984 (July), Senior Registrar, Department of Endocrinology, Hippokraton Hospital (teaching), Athens (Head, Professor G. Tolis). Acting Head, January 1982 - July 1983.

- 1984 (September) - 1988 (December), Chef de Clinique, Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital Leiden, The Netherlands (Professor OLM Bijvoet).

- 1989 (January) - 1997 (September), Head, Clinical Investigation Unit, Department of Endocrinology and Metabolic Diseases, University Hospital Leiden, The Netherlands.

- 1989 (January) - 1997 (September), Associate Professor of Medicine and Director of Bone and Mineral Research, Department of Endocrinology and Metabolic Diseases, University of Leiden Medical School.

- 1998 (January) – 2012 (March). Professor of Internal Medicine (Diseases of Calcium and Bone Metabolism), Consultant Physician and Director of Bone and Mineral Research, Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center.

**Present appointment
(since April 2012):**

Professor of Medicine, Consultant/Advisor, The Leiden Center for Bone Quality, Leiden University Medical Center.

**Fellowships, scholarships,
prizes :**

- Hugh Percy Noble Scholarship (for investigation of food deficiencies and nutritional diseases).
- Sanderson Wells Trust Award (for research in cancer).
- The Astor Fellowship (The Middlesex Hospital Medical School, University of London, U.K.).
- Wellcome Trust Clinical Research Fellowship.
- The Boy Frame Memorial Award of the American Society for Bone and Mineral Research for "Excellence in the clinical field of bone metabolism"
- Lilian Clark Lectureship (and Visiting Professor), University of Texas, Southwestern Medical Center at Dallas, USA.

- The Sarnat Lecturship in Bone Biology, University of Tel Aviv, Israel.
- The John G. Haddad Award of the International Bone and Mineral Society “In recognition of outstanding contributions to clinical research in bone and mineral metabolism”
- Career Achievements Award, the Hellenic Society for the Study of Bone Metabolism
- The JB Johnson Award of the Paget Foundation USA "For advancing the understanding and management of Paget's disease of bone".
- The Novo Nordisk Award 2009 of the Dutch Society of Endocrinology “For contribution to the research and treatment of skeletal disorders”.
- The Pierre Delmas Award of the International Foundation of Osteoporosis “For outstanding personal contribution to the International Osteoporosis Foundation”.
- The Steven Boonen Award for Clinical Research of the European Calcified Tissue Society
- The Federic C Bartter Award of the American Society for Bone and Mineral Research for “For outstanding clinical investigation in disorders of Bone and Mineral Metabolism”
- Doctor Honoris Causa, University of Athens, Greece
- Doctor Honoris Causa, University of Thessaloniki, Greece

State Decorations:

- Commander of the Order of the Phoenix of the Hellenic Republic.
- Officer of the Order of Oranje-Nassau of the Queen of the Netherlands

**Professional Societies
(past and present):**

American Endocrine Society
 American Society for Bone and Mineral Research
 Bone and Tooth Society of Great Britain
 British Society for Endocrinology
 Dutch Society for Endocrinology
 Dutch Society for Calcium and Bone Metabolism
 European Society of Calcified Tissues
 Greek Endocrine Society
 International Bone and Mineral Society
 Medical Research Society of Great Britain.
 The Hellenic Society for the Study of Bone Metabolism.

**Editorial Duties
(past and present):**

- Editor, Clinical Research Section, of *Bone and Mineral*; (1989-1995); Associate Editor (1986 - 1989).
- Editorial Boards: *Osteoporosis International*, *Bone*, *Clinical Endocrinology*, *BONe Depeche*, *BONEKey*, *Osteoporosis Reports*, *Clinical Cases of Mineral and Bone Metabolism*, *Nature Reviews Endocrinology*, *Expert Review Endocrinology and Metabolism*, *Endocrine*.

Boards

(past and present):

- Member of the Board of Trustees and of the Board of Scientific Advisors of the International Osteoporosis Foundation (IOF), of the Board of Directors of the International Bone and Mineral Society (IBMS) and of the Board of the European Calcified Tissue Society (ECTS).
- President, Secretary, the Dutch Society for Calcium and Bone Metabolism.

Committees:

- European Commission Committee for establishing guidelines for the prevention and treatment of Osteoporosis in Europe. Co-Editor European Commission report on osteoporosis
- Senior Scientific Advisor European Union project: Osteoporosis in Europe: Call for Action
- WHO task force for the development of a world-wide strategy for the prevention and treatment of osteoporosis
- Co-Chair Publications Committee of the IBMS
- Advisory Committees of the Health Council of the Dutch Ministry of Health on urolithiasis and osteoporosis
- The Dutch Committee for the development of a national consensus for diagnosis and treatment of osteoporosis (CBO)
- Chairman study section Calcium and Bone metabolism of the National Organization for Scientific Research .

- Scientific Program Committees (*selected*);
International Workshops on Bisphosphonates, Davos, Switzerland (1994, 1996, 1998, 2000, 2002, 2004, 2006, 2008, 2010).
International Symposium on Clinical Disorders of Bone and Mineral Metabolism, Detroit, USA (1993, 2000)
International Conferences on Male Osteoporosis, Genova, Italy (2001, 2003, 2005)
International Congress on Paget's Disease of Bone, Sydney, Australia (1995)
International Congress of Endocrinology, San Francisco, USA (1996)
World Congress of Osteoporosis, Amsterdam, The Netherlands, 1996 (Co-Chair Local Committee)
European Congress of Endocrinology, Sevilla, Spain (1998)
European Congress of Osteoporosis, Berlin, Germany (1998)
International Bone and Mineral Society-European Calcified Tissue Society Congress, Geneva, Switzerland (2005)
European Calcified Tissue Society, Prague, Czech Republic (2006).
Chair, International Bone and Mineral Society Congress, Toronto, Canada (2007).
European Calcified Tissue Society. Vienna, Austria (2009).
European Calcified Tissue Society, Athens, Greece (2011); Chair Local Committee.
Osteorheumatology International Congress, Genova, Italy (2011, 2013, 2015, 2016)

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, WCO-IOF-ESCEO (2014, 2015, 2016, 2017)

Other:

- Course leader IOF Postgraduate Course on Osteoporosis and other Bone diseases.
- Associate Editor of the ASBMR “*Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*”.
- Member of the task forces of ASBMR and IOF-ECCEO on atypical fractures of the femur
- Member of the IOF (ESCEO) working groups on the use of FRAX in clinical practice, the effects of treatments on fracture healing, goal-directed treatment for osteoporosis, management of glucocorticoid-induced osteoporosis and rare bone diseases
- Medical advisor to the Dutch Society of Patients with Paget’s Disease
- Member, International Medical Advisory Panel of the Paget’s Foundation, USA

Research funding in The Netherlands (past and present):

The Dutch Organization for Scientific Research (MW-NWO, Programme and Project grants)
European Union (co-ordinator FP7 project)
The Dutch Kidney Foundation
The Dutch Cancer Society
The Dutch Prevention Fund
The Royal Academy of Sciences (KNAW)
Ziekenfondsraad (Ontwikkelingsgeneeskunde)
Dutch Society of Patients with Paget’s Disease
The Industry.

Teaching:

Continuous engagement in teaching at undergraduate and postgraduate levels in Greece, The UK and The Netherlands.

(Co-) Supervision PhD Dissertations:

DJ Kok : The role of crystallization processes in calcium oxalate urolithiasis (Cum Laude) - 1991.

K Hoekman : Tumor-induced bone resorption - 1991.

G.van der Pluijm :Modulation of osteoclastic resorption by bisphosphonates and cytokines - 1992.

R Valkema : Photon absorptiometry in the follow-up of bone mineral content; reproducibility of the technique and clinical application in patients with osteoporosis treated with the bisphosphonate pamidronate - 1992.

ATM van Holten-Verzantvoort : Palliative bisphosphonate treatment of metastatic bone disease - 1993.

W Most: Modulation of osteoclastic bone resorption by sex steroids - 1995.

F Eggelmeijer: Bone metabolism, bone mass and effects of pamidronate therapy in rheumatoid arthritis - 1995.

DH Schweitzer: Pathophysiology of tumour hypercalcaemia and Paget's disease of bone and treatment with new bisphosphonates.- 1996.

JO Landman: Long-term effects of bisphosphonate (pamidronate) therapy in osteoporosis - 1996.

M Deckers: Building Bones: the role of VEGF-A in embryonic bone formation – 2001

RL Van Bezooijen: Cytokines and nitric oxide as modulators of bone and cartilage degradation – 2001

R Versluis: Osteoporosis in general practice, a diagnostic study - 2002

E Van Beek: Mechanism of action of bisphosphonates (Cum Laude) - 2002

R Pelger: Prostate cancer and the skeleton– 2003

EMW Eekhoff: Paget's disease in the Netherlands; epidemiology, genetics and treatment – 2004

S Cremers: Clinical pharmacokinetics and pharmacodynamics of bisphosphonates in metabolic bone diseases – 2004

G van der Horst: Regulation of osteoblast differentiation (the role of major morphogenic signaling pathways and modulation by PTH/PTHrP signaling) – 2005.

V Soerdjbalie-Maikoe: Hormone-refractory prostate cancer and the skeleton – 2006

J T Buijs: Pathogenesis and treatment of skeletal metastasis; studies in animal models – 2008

A van Lierop: Sclerostin, a key regulator of bone metabolism - 2013

PUBLICATIONS

A. CHAPTERS

- A1. Papapoulos SE, Lewin IG, Clemens TL, Hendy GN, O'Riordan JLH.
Vitamin D
In: Gray CH, James VHT eds. *Hormones in Blood* , 3rd Edition. London:
Academic Press, 1979; 2:53-95.
- A2. Hendy GN, Papapoulos SE, Lewin IG, O'Riordan JLH.
Parathyroid Hormone
In: Gray CH, James VHT eds. *Hormones in Blood* , 3rd Edition. London:
Academic Press, 1979; 2: 1-52.
- A3. Papapoulos SE.
Hormonal Control of Calcium Metabolism in Pregnancy and Lactation
In: Prevedourakis K, Soublis A, Papathanassiou Z eds. *Current Topics in
Obstetrics and Gynaecology*. Athens: Kovanis, 1980; 2: 217-241. (*in Greek*)
- A4. Papapoulos SE.
Hypocalcaemia
In: Avramides A ed. *Emergencies in Endocrinology* . Thessaloniki:
University Studio Press, 1983: 65-76. (*in Greek*)
- A5. Papapoulos SE, O'Riordan JLH.
Bone
In: Cambell EJM, Dickinson CJ, Slater JDH eds. *Clinical Physiology* , 5th
Edition. London: Blackwells 1984: 310-342.
- A6. Papapoulos SE.
Andere vormen van hypercalcaemie
In: Juttman JR, Lockfeer JHM eds. *Metabole Botziekten*.. Utrecht: Bunge
1988: 194-203.
- A7. Goslings BM, Krans HMJ, Papapoulos SE, Roelfsma F.
Endocrinologie.
In: den Ottolander GJH ed. *Interne Geneeskunde*, 10th Edition. Houten: Bohn
Stafleu van Loghum 1992: 660-702.
- A8. Hamdy NAT, Schweitzer D, Papapoulos SE.
Regulatie en stornissen van calcium, fosfaat en magnesium huishouding.
In: Koomans H, Weening J, De Jong S eds. *Klinische Nefrologie*. Utrecht:
Bunge, 1992 : 131-141.
- A8a. idem; 2nd Edition, 1996: 147-158.
- A9. Breedveld FC, Dantenberg PLJ, Duursma SA, de Fockert JA, Jongbloed JC, vd
Linden S, Lips PTAM, Papapoulos SE, Roos RHC.

Het bewegen: gaan, staan en doen wat men wil.
In: Euldrink F, Heeren TJ, Knook DL, Ligthart GJ eds. *Inleiding Gerontologie, Geriatrie*. Houten: Bohn Stafleu van Loghum, 1993: 105-142.

- A9a. idem; 2nd Edition, 1995: 105-143.
- A10. Papapoulos SE.
Idiopathic juvenile osteoporosis.
In: Nordin BEC, Need AG, Morris HA eds. *Metabolic Bone and Stone Disease*, 3rd Edition. London: Churchill Livingstone, 1993 : 81-82.
- A11. Papapoulos S.
Farmacologia clinica dei difosfonati.
In: Filipponi P ed. *Osteoporosi: clinica e terapia nella realta internazionale*, Milano: Promopharma srl, 1994: 58-71.
- A12. Papapoulos SE.
Bisfosfonati nel trattamento della osteoporosi stabilizzata.
In: Passeri M, Adami S eds. *I bisfosfonati nella pratica clinica*, Pisa: Edizioni ETS, 1994: 319-330.
- A13. Papapoulos SE.
Treatment of established osteoporosis with bisphosphonates.
In: Bijvoet OLM, Canfield R, Fleisch H, Russell G eds. *Bisphosphonate on Bones*, Amsterdam: Elsevier Science, 1995: 403-418.
- A14. Papapoulos SE.
Pharmacodynamics of bisphosphonates in man; implications for treatment..
In: Bijvoet OLM, Canfield R, Fleisch H, Russell G eds. *Bisphosphonate on Bones*, Amsterdam: Elsevier Science, 1995: 231-245.
- A15. Papapoulos SE.
Bisphosphonates: Pharmacology and use in the treatment of osteoporosis.
In: Marcus R, Feldman D, Kelsey J eds. *Osteoporosis*, New York: Academic Press, 1996: 1209-1233.
- A16. Papapoulos SE.
Miscellaneous causes of osteoporosis.
In: Favus MJ et al eds. *Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism* (3rd Edition), New York: Raven Press, 1996; 289- 293.
- A17. Papapoulos SE, Lips P, Pols H, Johnston C, Delmas PD eds.
Osteoporosis 96, Proceedings of the 1996 World Congress on Osteoporosis, Amsterdam, Elsevier Science, 1996.
- A18. Papapoulos SE.
Aandoeningen van calcium- en botstofwisseling.
In: van der Meer J, Stehouwer CDA, Ottolander GJH eds. *Interne Geneeskunde* (11de druk), Hoofdstuk 18: Endocrinologie, Houten: Bohn Stafleu van Loghum, 1996: 878-890.

- A19: Papapoulos SE.
Paget's disease of bone: clinical, diagnostic and therapeutic aspects.
In: Reid IR ed. Metabolic Bone Disease. *Bailliere's Clinical Endocrinology and Metabolism* 1997; 11: 117-143.
- A20. O'Neill T, Papapoulos SE.
Can we prevent fractures?
In: Delmas PD, Woolf AD eds. Osteoporosis
Bailliere's Clinical Rheumatology 1997; 11: 565-582.
- A21. Papapoulos SE.
Miscellaneous causes of osteoporosis.
In: Favus MJ ed. *Osteoporosis: Fundamentals of Clinical Practice* Philadelphia: Lippincott-Raven, 1997: 117-121.
- A22. Papapoulos SE.
Paget's disease of bone.
In: Thakker R, Wass J (eds). *Medicine: Endocrine; Metabolic Bone Disease* 1997; 25; 6: 81-83.
- A23. Papapoulos SE.
De waarde van bisfosfonaten bij osteoporose.
In: Duursma SA (ed). *Osteoporose, osteomalacie en de ziekte van Paget* Maarssen: Elsevier/Bunge, 1998: 71-76.
- A24. Eekhoff EMW, Papapoulos SE.
De ziekte van Paget.
In: Duursma SA (ed). *Osteoporose, osteomalacie en de ziekte van Paget* Maarssen: Elsevier/Bunge, 1998: 101-108.
- A25. Compston JE, Papapoulos SE, Blanchard F eds.
Report on Osteoporosis in the European Community, European Communities/European Foundation for Osteoporosis, 1998.
- A26. Papapoulos SE.
Bisphosphonates
In: Rosen CJ, Glowacki J, Bilezikian JP (eds). *The Aging Skeleton*, Academic Press, San Diego, 1999: 541-549.
- A27. Goslings BM, Papapoulos SE, Roelfsma F, Romijn JA.
Endocrinologie
In: van der Meer J and Stehouwer CDA (eds). *Interne Geneeskunde* (12^{de} druk), Bohn, Stafleu, van Loghum, Houten, 2001; 679-736.
- A28. Papapoulos SE.
Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J eds. *Osteoporosis* (2nd Edition), New York: Academic Press, 2001; Vol 2:631-650.

- A29. Papapoulos SE.
Miscellaneous bone diseases (Paget's disease, fibrous dysplasia, osteopetrosis, Gaucher's disease, osteogenesis imperfecta).
In: Pinchera A et al (eds). *Endocrinology and Metabolism*, McGraw-Hill, Maidenhead, 2001; pp255-266.
- A30. Papapoulos SE.
Ectopic calcification and ossification.
In: Pinchera A et al (eds). *Endocrinology and Metabolism*, McGraw-Hill, Maidenhead, 2001; pp267-270.
- A31. Papapoulos SE.
Paget's disease of bone.
In: Wass J, Schalet S (eds). *Oxford Textbook of Endocrinology and Diabetes*, Oxford University Press, Oxford 2002; pp 685-695.
- A32. Papapoulos SE
Paget's disease of bone.
In: Isenberg DA et al (eds). *Oxford Textbook of Rheumatology*, Oxford University Press, Oxford, 2004; pp1148-1156.
- A33. Papapoulos SE
Bisphosphonates.
In: Woolf AD et al (eds). *The Year in Osteoporosis 1*, Atlas Medical Publishing, Oxford, 2004; pp 247-267.
- A34. Papapoulos SE.
Metastatic bone disease.
In: Kleerekoper M, Siris E, McClung M (eds). *The Bone and Mineral Manual*, Elsevier Inc, Amsterdam, 2005; pp 138-139.
- A35. Romijn JA, Smit JWA, Papapoulos SE.
Endocrinologie
In: van der Meer J and Stehouwer CDA (eds). *Interne Geneeskunde* (13^{de} druk), Bohn, Stafleu, van Loghum, Houten, 2005; 673-727..
- A36. Papapoulos SE
Management of osteoporosis: bisphosphonates.
In: Akesson K et al (eds). *The Year in Osteoporosis 2*, Atlas Medical Publishing, Oxford, 2006; pp 257-279.
- A37. Papapoulos SE.
Bisphosphonates in the management of osteoporosis.
In: Genazzani AR (ed). *Postmenopausal Osteoporosis*, Taylor & Francis, Oxford, 2006: pp 209-217.
- A38. Bouillon, R, Pols HAP, Lips PTAM, Hamdy NAT, Papapoulos SE.
Metabole botziekten.
In: Krenning EP et al (eds) *Endocrinologie*, Elsevier Health, Maarsen, 2007: pp 161-184.

- A39. Papapoulos SE.
Bisphosphonates for postmenopausal osteoporosis.
In: Rosen CJ (ed) ***Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism***, American Society for Bone and Mineral Research, Washington DC, 2008: pp 237-241.
- A39a. idem: 8th Edition, 2013, pp 412-419.
- A40. van Bezooijen RL, Papapoulos SE, Hamdy NAT, Lowik CWGM.
SOST/Sclerostin: an osteocyte-derived inhibitor of bone formation that antagonizes canonical Wnt signaling.
In: Bilezikian JP, Raisz LG, Martin TJ (eds) ***Principles of Bone Biology***, Academic Press, San Diego, 2008; pp 139-152
- A41. Giusti A, Papapoulos SE
Treatment of male osteoporosis with bisphosphonates.
In: Orwoll ES et al (eds) ***Osteoporosis in Men*** Academic Press, 2010; pp 667- 679.
- A42. Papapoulos SE
Paget's disease of bone.
In: Wasss AH, Stewart P (eds) ***Oxford Textbook of Endocrinology and Diabetes 2nd Edition***. Oxford University Press, Oxford 2011; pp 721-730.
- A43. Papapoulos SE
Long-term efficacy and safety of treatments for osteoporosis.
In: Silverman SL, Abrahamsen B (eds) ***The Duration and Safety of Osteoporosis Treatment***. Springer International Publishing, Switzerland 2016; pp 203-232.
- A44. Van Lierop A, Papapoulos SE
Circulating sclerostin in bone sclerosing disorders
In: Preedy VR (ed) ***Biomarkers in Bone Disease, Biomarkers in Disease: Methods, discoveries and application***. Springer Science + Business Media, Doordrecht 2016; DOI 10-1007/978-94-007-7745-3_39-1.
- A45. Papapoulos SE
Focal bone diseases.
In: ***Oxford Desk Reference Endocrinology***. In Press.

B. ARTICLES IN PEER-REVIEWED JOURNALS

- B1. Sehas MN, Plessas SN, Panagopoulos E, Stamatelos G, Papapoulos SE, Skalkas G.
Renovascular hypertension due to A-V fistula between the renal artery and the inferior vena cava.
Greek Surgery 1974; 46: 50-54
- B2. Stamatelos G, Papapoulos SE, Pagalis G, Pagali A, Fessas P.
The syndrome of incomplete renal tubular acidosis.
Minerva Medica Greca 1975; 3: 548-554.
- B3. Contoyiannis PA, Papapoulos SE, Mortoglou AA.
Co-trimoxazole in chronic brucellosis. A two year follow-up.
British Medical Journal 1975; 2: 480-481.
- B4. Lewin IG, Hendy GN, Papapoulos SE, Tomlinson S, O'Riordan JLH.
Plasma adenosine 3',5'-cyclic monophosphate: dose response to injected bovine parathyroid hormone in man.
Calcified Tissue Research 1977; 22: 332-335.
- B5. Papapoulos SE, Hendy GN, Tomlinson S, Lewin IG, O'Riordan JLH.
Clearance of exogenous parathyroid hormone in normal and uraemic man.
Clinical Endocrinology 1977; 7: 211-225.
- B6. Lewin IG, Papapoulos SE, O'Riordan JLH.
1 α -hydroxycholecalciferol in the long-term management of hypoparathyroidism and pseudohypoparathyroidism.
Clinical Endocrinology 1977; 7s: 203-207.
- B7. Papapoulos SE, Brownjohn AM, Junor BJR, Marsh FP, Goodwin FJ, Hatley W, Lewin IG, Hendy GN, Tomlinson S, O'Riordan JLH.
Hyperparathyroidism in chronic renal failure.
Clinical Endocrinology 1977; 7s: 59-65.
- B8. Brownjohn AM, Goodwin FJ, Marsh FP, O'Riordan JLH, Papapoulos SE.
1 α -hydroxycholecalciferol for renal osteodystrophy.
British Medical Journal 1977; 2:721-723.
- B9. Care AD, Pickard DW, Papapoulos SE, O'Riordan JLH, Redel J.
Inhibitory effect of 25,26-dihydroxycholecalciferol on the rate of secretion of parathyroid hormone in goats.
Journal of Endocrinology 1978; 78: 303-304.
- B10. Page CM, Hulme B, Papapoulos SE, O'Riordan JLH.
Avascular necrosis of bone after renal transplantation; the role of vitamin D and parathyroid hormone.
British Medical Journal 1978; 2: 664-665.
- B11. Lewin IG, Papapoulos SE, Tomlinson S, Hendy GN, O'Riordan JLH.
Studies of hypoparathyroidism and pseudohypoparathyroidism
Quarterly Journal of Medicine 1978; 47: 533-548.
- B12. Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O'Riordan JLH.
1,25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis.
Lancet 1979; i: 627-630.
- B13. Clemens TL, Hendy GN, Papapoulos SE, Fraher LJ, Care AD, O'Riordan JLH.

- Measurement of 1,25-dihydroxycholecalciferol in man by radioimmunoassay.
Clinical Endocrinology 1979; 11: 225-234.
- B14. Jones MK, Papapoulos SE.
Control of hypercalcaemia in thyrotoxicosis.
Postgraduate Medical Journal 1979; 58: 891-898.
- B15. Dunlop DAB, Papapoulos SE, Lodge RW, Fulton AJ, Kendall BE, O'Riordan JLH.
Parathyroid venous sampling: anatomic considerations and results in 95 patients with primary hyperparathyroidism.
British Journal of Radiology 1980; 53: 183-191.
- B16. Papapoulos SE, Manning RM, Hendy GN, Lewin IG, O'Riordan JLH.
Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay.
Clinical Endocrinology 1980; 13: 57-67.
- B17. Parsons V, Papapoulos SE, Weston MJ, Tomlinson S, O'Riordan JLH.
The long-term effect of lowering dialysate magnesium on circulating parathyroid hormone in patients on regular haemodialysis.
Acta Endocrinologica 1980; 93: 455-460.
- B18. Manning RM, Hendy GN, Papapoulos SE, O'Riordan JLH.
The development of homologous immunological assays for human parathyroid hormone.
Journal of Endocrinology 1980; 85: 161-170.
- B19. Liberman US, Samuel R, Halabe A, Kauli R, Edelstein S, Weisman Y, Papapoulos SE, Clemens TL, Fraher LJ, O'Riordan JLH.
End-organ resistance to 1,25-dihydroxycholecalciferol.
Lancet 1980; i: 504-507.
- B20. Fraher LJ, Clemens TL, Papapoulos SE, Redel J, O'Riordan JLH.
Determination of circulating 25,26-dihydroxycholecalciferol in man by radioimmunoassay.
Clinical Science 1980; 59: 257-263.
- B21. Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O'Riordan JLH.
Metabolites of vitamin D in human vitamin D deficiency: effect of vitamin D₃ or 1,25-dihydroxycholecalciferol.
Lancet 1980; ii: 612-615.
- B22. Nagant de Deuxchaisnes C, Devogelaer JP, Rombouts-Lindemans C, Huaux JP, Withofs H, Meersseman F, Sorel L, Papapoulos SE, Clemens TL, Fraher LJ, O'Riordan JLH.
Comparaison des taux seriques de 1,25-(OH)₂D₃ avec les parametres histomorphometriques de l' osteomalacie dans les troubles du metabolisme de la vitamine D.
Annales d' Endocrinologie (Paris) 1980; 41: 441-443.
- B23. Papapoulos SE, Adami S, O'Riordan JLH.
Hormonal resistance in disorders of calcium homeostasis.
Annals of Clinical Research 1980; 12: 254-263.
- B24. Papapoulos SE, Kalomenopoulou M, Beis I.
Hormonal Control of calcium metabolism. The vitamin D endocrine system.
Minerva Medica Greca 1980; 8: 418-430.
- B25. Manning RM, Adami S, Papapoulos SE, Gleed JL, Hendy GN, Rosenblatt M, O'Riordan JLH.

- A carboxy-terminal specific assay for human parathyroid hormone.
Clinical Endocrinology 1981; 15: 439-449.
- B26. Papapoulos SE, Clemens TL, Sandler LM, Fraher LJ, Winer J, O'Riordan JLH
The effect of renal function on changes in circulating concentrations of
1,25-dihydroxycholecalciferol after an oral dose.
Clinical Science 1982; 62: 427-431.
- B27. Lewin IG, Papapoulos SE, Hendy GN, Tomlinson S, O'Riordan JLH.
Reversible resistance to the renal action of parathyroid hormone in
vitamin D deficiency.
Clinical Science 1982; 62: 381-387.
- B28. Canningham J, Fraher LJ, Clemens TL, Revel PA, Papapoulos SE.
Chronic acidosis with metabolic bone disease. Effect of alkali on bone
morphology and vitamin D metabolism.
American Journal of Medicine 1982; 62: 381-387.
- B29. Sharman VL, Brownjohn AM, Goodwin FJ, Hately W, Manning RM,
O'Riordan JLH, Papapoulos SE, Marsh FP.
Long-term experience of alfacalcidol in renal osteodystrophy.
Quarterly Journal of Medicine 1982; 51: 271-
- B30. Care AD, Ross R, Pickard DW, Weatherley AJ, Garel JM, Manning RM,
Allgrove J, Papapoulos SE, O'Riordan JLH.
Calcium homeostasis in the fetal pig.
Journal of Developmental Physiology 1982; 4: 85-106.
- B31. Adami S, Muirhead N, Manning RM, Gleed JH, Papapoulos SE, Sandler LM,
Catto GRD, O'Riordan JLH.
Control of secretion of parathyroid hormone in secondary hyperparathy-
roidism.
Clinical Endocrinology 1982; 16: 463-473.
- B32. Adami S, Frijlink WB, Bijvoet OLM, O'Riordan JLH, Clemens TL, Papapou-
los SE.
Regulation of calcium absorption by 1,25-dihydroxyvitamin D - studies
of the effects of a bisphosphonate treatment.
Calcified Tissue International 1982; 34: 317-320.
- B33. Lewin IG, Hendy GN, Papapoulos SE, Tomlinson S, O'Riordan JLH.
Effect of renal function on renal responsiveness to parathyroid hormone
in primary hyperparathyroidism and chronic failure.
European Journal of Clinical Investigation 1985; 15: 38-44.
- B34. Hoekman K, Papapoulos SE, Peters ACB, Bijvoet OLM.
Characteristics and bisphosphonate treatment of a patient with juvenile
osteoporosis.
Journal of Clinical Endocrinology and Metabolism 1985; 61: 952-
956.
- B35. Fraher LJ, Adami S, Papapoulos SE, Sudan HL, McGonigle RJ, Parsons V,
O'Riordan JLH.
Evidence for extrarenal metabolism of 25-hydroxyvitamin D₃ in man.
Clinical Science 1986; 71: 89-95.
- B36. Papapoulos SE, Harinck HIJ, Bijvoet OLM, Gleed JH, Fraher LJ, O'Riordan

- JLH.
Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Bone and Mineral 1986; 1: 69-78.
- B37. Baker LRI, Muir JW, Sharman VL, Abrams SML, Greenwood RN, Catell WR, Goodwin FJ, Marsh FP, Adami S, Hately W, Hattersley LA, Morgan AG, Papapoulos SE, Revell PA, Tucker AK, Chaput de Santogne DM, O'Riordan JLH.
Controlled trial of calcitriol in haemodialysis patients.
Clinical Nephrology 1986; 26: 185-191.
- B38. Kok DJ, Papapoulos SE, Bijvoet OLM.
Excessive crystal agglomeration with low citrate excretion in recurrent stone formers.
Lancet 1986; i: 1056-1058.
- B39. Papapoulos SE, Steendijk R, Bijvoet OLM.
A tumour-like bone lesion as a manifestation of vitamin D resistant hypophosphataemic osteomalacia.
British Journal of Radiology 1987; 60: 285-286.
- B40. Papapoulos SE, Frölich M, Mudde AH, Harinck HIJ, vd Berg H, Bijvoet OLM
Serum osteocalcin in Paget's disease of bone. Basal concentrations and response to bisphosphonate treatment.
Journal of Clinical Endocrinology and Metabolism 1987; 65:89-94.
- B41. Mudde AH, vd Berg H, Boshuis PG, Breedveld FC, Markusse HM, Kluin PM, Bijvoet OLM, Papapoulos SE.
Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcaemia.
Cancer 1987; 59: 1453-1456.
- B42. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OLM.
Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate
British Medical Journal 1987; 295: 1301-1305.
- B43. Papapoulos SE.
Regulation of parathyroid hormone secretion by calcium in man.
Frontiers in Hormone Research 1987; 17: 211-220.
- B44. Kok DJ, Papapoulos SE, Blomen LJM, Bijvoet OLM.
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.
Kidney International 1988; 34: 346-350.
- B45. Papapoulos SE, vd Berg H, Frölich M, Valentijn RM
Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 α -hydroxycholecalciferol in patients on regular haemodialysis.
Nephrology Dialysis Transplantation 1988; 3: 647-650.
- B46. Macfarlane JD, Papapoulos SE.
Alkalische-fosfatasegehalte bij botziekten; vaak te hoog, soms te laag.
Nederlands Tijdschrift Voor Geneeskunde 1989; 133: 1679-1683.
- B47. Valkema R, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ.
Photon absorptiometry: merits and problems in clinical practice.
Journal of Medical Imaging 1989; 3: 255-264.

- B48. Valkema R, Vismans F-JE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. *Bone and Mineral* 1989; 5: 183-192.
- B49. Valkema R, van den Berg R, Camps JAJ, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ. Precision of dual photon absorptiometry measurements: comparison of three different methods of selection of the region of interest. *European Journal of Nuclear Medicine* 1989; 15: 183-188.
- B50. Valkema R, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ. The reproducibility of single photon absorptiometry in a clinical setting. *European Journal of Nuclear Medicine* 1989; 15: 269-273.
- B51. Löwik CWGM, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OLM, Aarden LA, Papapoulos SE. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate Interleukin-6 production by osteogenic cells: a possible role of Interleukin-6 in osteoclastogenesis. *Biochemical and Biophysical Research Communications* 1989; 162: 1546-1552.
- B52. Roelen DL, Frölich M, Papapoulos SE. Renal responsiveness to synthetic human parathyroid hormone 1-38 in healthy subjects. *European Journal of Clinical Investigation* 1989; 19: 311-315.
- B53. Papapoulos SE, Hoekman K, Löwik CWGM, Vermeij P, Bijvoet OLM. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. *Journal of Bone and Mineral Research* 1989; 4: 775-781.
- B54. Pelger RCM, Lycklama a Nijeholt AAB, Papapoulos SE. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. *The Lancet* 1989; ii: 865 (letter) .
- B55. Maaswinkel-Mooij PD, Papapoulos SE, Gerritsen EJA, Mudde AH, Van de Kamp JJP. Facial dysmorphism, parathyroid and thymic dysfunction in the father of a newborn with the DiGeorge complex. *European Journal of Pediatrics* 1989; 149: 179-183.
- B56. Frölich M, Walma ST, Paulson C, Papapoulos SE. Immunoradiometric assay for intact parathyroid hormone: characteristics, clinical application and comparison with a radioimmunoassay. *Annals of Clinical Biochemistry* 1990; 27: 69-72.
- B57. Kok DJ, Papapoulos SE, Bijvoet OLM. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. *Kidney International* 1990; 37: 51-56.
- B58. Doorenbos CJ, Iestra JA, Papapoulos S, Odink J, van Brummelen P. Atrial natriuretic peptide and chronic renal effects of changes in dietary protein and

- sodium intake in man.
Clinical Science 1990 ; 78, 565-572
- B59. Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE.
 The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men.
Journal of Clinical Endocrinology and Metabolism 1990; 71: 861-867
- B60. Valkema R, Verheij LF, Blokland JAK, Zwinderman AH, Bijvoet OLM, Papapoulos SE, Pauwels EKJ.
 Limited precision of lumbar spine dual photon absorptiometry by variations in the soft tissue background.
Journal of Nuclear Medicine 1990; 31: 1774-1781.
- B61. Hoekman K, Löwik CWGM, vd Ruit M, Bijvoet OLM, Verheijen JH, Papapoulos SE.
 Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.
Bone and Mineral 1991 ; 14: 189-204.
- B62. Papapoulos S.
 Bisphosphonate in der Behandlung der Osteoporose.
Therapeutische Umschau 1991; 48: 100-106.
- B63. Papapoulos SE, Lockefeer JHM
 Bisfosfonaten bij de behandeling van osteoporose.
Nederlands Tijdschrift Voor Geneeskunde 1991; 135: 553-556.
- B64. van der Pluijm G, Löwik CWGM, de Groot H, Alblas MJ, vd Wee-Pals L, Bijvoet OLM, Papapoulos SE.
 Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants.
Journal of Bone and Mineral Research 1991 ; 11: 1203-1210.
- B65. van der Pluijm G, Most W, vd Wee-Pals L, de Groot H, Papapoulos SE, Löwik CWGM.
 Two distinct effects of recombinant human tumor necrosis factor alpha on osteoclast development and subsequent resorption of mineralized matrix.
Endocrinology 1991 ; 129: 1596-1604.
- B66. Verheij LF, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ.
 Automated comparison of dual-photon absorptiometric studies of the lumbar spine.
Journal of Bone and Mineral Research 1991; 6: 575-581.
- B67. Verheij LF, Blokland JAK, Vossepoel AM, Valkema R, Camps JAJ, Papapoulos SE, Bijvoet OLM, Pauwels EKJ.
 Automatic region of interest determination in dual photon absorptiometry of the lumbar spine.
Transactions of Medical Imaging 1991; 10: 200-206.
- B68. Hoekman K, Tjandra Y, Papapoulos SE.
 The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein.
Cancer 1991; 68: 642-647.
- B69. Macfarlane JD, Frolich M, Papapoulos SE.
 Serum osteocalcin levels before and after 1,25-dihydroxyvitamin D stimulation in a family with hypophosphatasia
Bone 1991; 12: 261-263.
- B70. Lycklama a Nijeholt GAB, Tan HKS, Papapoulos SE.
 Metabolic evaluation in stone patients in relation to extracorporeal shock wave lithotripsy treatment.

- Journal of Urology* 1991; 146: 1478-1481.
- B71. Löwik CWGM, Hoekman K, Offringa R, Groot CG, Hendy GN, Papapoulos SE, Ponec M.
Regulation of parathyroid hormone-like protein production in cultured normal and malignant keratinocytes.
Journal of Investigative Dermatology 1992; 98: 198-203.
- B72. Sloomweg R, Most WW, van Beek E, Schot LPC, Papapoulos SE, Löwik CWGM.
Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin growth factor I.
Journal of Endocrinology 1992; 132: 433-438.
- B73. Papapoulos SE, Landman JO, Bijvoet OLM, Löwik CWGM, Valkema R, Pauwels EKJ, Vermeij P.
The use of bisphosphonates in the treatment of osteoporosis.
Bone 1992; 13: S41-S49.
- B74. Hoekman K, Löwik CWGM, vd Ruit M, Bivoet OLM, Verheijen JH, Papapoulos SE.
The effect of tissue type plasminogen activator (tPA) on osteoclastic resorption in embryonic mouse long bone explants. A possible role for the growth factor domain of tPA.
Bone and Mineral 1992; 17: 1-13.
- B75. vd Pluijm G, Binderup L, Bramm E, vd Wee-Pals L, de Groot H, Binderup E, Löwik C, Papapoulos S.
Disodium 1-hydroxy-3-(1-pyrrolidiny)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
Journal of Bone and Mineral Research 1992; 7: 981-986.
- B76. Verheij LF, Blokland JAK, Papapoulos SE, Zwinderman AH, Pauwels EKJ.
Optimization of follow-up measurements of bone mass.
Journal of Nuclear Medicine 1992; 33: 1406-1410.
- B77. van Persijn-van Meerten EL, Kroon HM, Papapoulos SE.
Epi- and metaphyseal changes in children caused by bisphosphonates.
Radiology 1992; 184: 249-254.
- B78. Brumsen C, Bloem RM, Papapoulos SE.
Paget's disease with osteolytic lesions; combining medical and surgical treatments.
The Netherlands Journal of Medicine 1992; 40: 292-298.
- B79. Papapoulos SE, van Holten-Verzandvoort ATM.
Modulation of tumour-induced bone resorption by bisphosphonates.
Journal of Steroid Biochemistry and Molecular Biology 1992; 43: 131-136.
- B80. van Beek E, van der Wee-Pals L, van de Ruit M, Nijweide P, Papapoulos S, Löwik C.
Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization and alkaline phosphatase activity in fetal mouse metacarpal bones in culture.
Journal of Bone and Mineral Research 1993; 8: 191-198.
- B81. Eggelmeijer F, Papapoulos SE, Westedt ML, van Paassen C, Dijkmans BAC, Breedveld FC.
Bone metabolism in rheumatoid arthritis; relation to disease activity.
British Journal of Rheumatology 1993; 32: 387-391
- B82. Kok DJ, Papapoulos SE.
Physicochemical considerations in the pathogenesis and prevention of calcium oxalate urolithiasis.
Bone and Mineral 1993; 20: 1-15.
- B83. Schweitzer DH, Zwinderman AH, Bijvoet OLM, Vermey P, Papapoulos SE.
Improved treatment of Paget's disease with dimethyl-aminohydroxypropylidene bisphosphonate (dimethyl-APD).

- Journal of Bone and Mineral Research* 1993; 8: 175-182.
- B84. Bijvoet OLM, Valkema R, Löwik CWGM, Papapoulos SE.
Bisphosphonates in osteoporosis?
Osteoporosis International 1993; 3 (Suppl 1): 230-236.
- B85. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleenboom HP, Vermey P, Zwinderman AH.
Palliative pamidronate (APD) treatment in patients with bone metastases from breast cancer.
Journal of Clinical Oncology 1993; 11: 491-498.
- B86. Hamdy NAT, Papapoulos SE, Coldwell A, Eastell R, Russell RGG.
Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
Bone and Mineral 1993; 22: 1-8.
- B87. Eggelmeijer F, Camps JAJ, Valkema R, Papapoulos SE, Pauwels EKJ, Dijkmans BAC, Breedveld FC.
Bone mineral density in ambulant, non-steroid treated female patients with rheumatoid arthritis.
Clinical and Experimental Rheumatology 1993; 11: 381-385.
- B88. Löwik CWGM, Alblas MJ, vd Ruit M, Papapoulos SE, vd Pluijm G.
Quantification of adherent and non-adherent cells cultured in 96-well plates using the supravital stain neutral red.
Analytical Biochemistry 1993; 213: 426-433.
- B89. Papapoulos SE.
The role of bisphosphonates in the prevention and treatment of osteoporosis.
American Journal of Medicine 1993; 95 (5A): 48-52.
- B90. Papapoulos SE.
Strategies of treatment of Paget's disease with bisphosphonates.
Seminars in Arthritis and Rheumatism 1994; 23: 426-433.
- B91. Koopmans SJ, vd Wee-Pals L, Löwik CWGM, Papapoulos SE.
The use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment; application to the study of intravenous ¹⁴C-labelled 1-hydroxy-3-(1-pyrrolinidyl)-propylidene-1,1-bisphosphonate.
Journal of Bone and Mineral Research 1994; 9: 241-246.
- B92. Löwik CWGM, Nibbering PH, vd Ruit M, Papapoulos SE.
Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic resorption.
Journal of Clinical Investigation 1994; 93: 1465-1472.
- B93. Pollak MR, Chou YHW, Marx SJ, Steinmann B, Cle DEC, Brandi ML, Papapoulos SE, Menko F, Hendy GN, Brown EM, Seidman CE, Seidman JG.
Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism: the effects of mutant gene dosage on phenotype.
Journal of Clinical Investigation 1994; 25: 1108-1112.
- B94. Denissen H, van Beek E, Löwik C, Papapoulos S, Kalk W, vd Hooff A.
Ceramic hydroxyapatite implants for the release of bisphosphonate.
Bone and Mineral 1994; 25: 123-134
- B95. van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Löwik C.
Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp (RGD) peptides during osteoclast formation.
Journal of Bone and Mineral Research 1994; 9: 1021-1028.

- B96. Eggelmeijer F, Papapoulos SE, van Passen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis; a double-blind, placebo-controlled study. *Journal of Rheumatology* 1994; 21: 2016-2020.
- B97. Schweitzer DH, Hamdy NAT, Frölich M, Zwinderman AH, Papapoulos SE. Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. *Clinical Endocrinology* 1994; 41: 251-256.
- B98. Samuel R, Katz K, Papapoulos SE, Yosef Y, Raizov R, Liberman UA. Aminohydroxypropylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. *Pediatrics* 1994; 94: 385-389.
- B99. Valkema R, Pripic H, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ. Dual photon absorptiometry for bone mineral measurements using a gamma camera. *Acta Radiologica* 1994; 35: 45-52.
- B100. van Beek E, Hoekstra M, van de Ruit M, Löwik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. *Journal of Bone and Mineral Research* 1994; 9: 1875-1882.
- B101. van Schaardenburg D, Valkema R, Dijkmans BAC, Papapoulos S, Zwinderman A, Han H, Breedveld FC. Prednisone treatment of elderly-onset rheumatoid arthritis: disease activity and bone mass in comparison to chloroquin treatment. *Arthritis and Rheumatism* 1995; 38: 334-342.
- B102. Weissglas M, Schamhart D, Löwik C, Papapoulos S, Vos P, Kurth KH. Hypercalcaemia and cosecretion of Interleukin-6 and Parathyroid Hormone-related Peptide by a human renal cell carcinoma implanted into nude mice. *Journal of Urology* 1995; 153: 854-857.
- B103. Landman JO, Papapoulos SE. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone (PTH) secretion. *Osteoporosis International* 1995; 5: 93-96.
- B104. Boxman ILA, Quax PHA, Löwik CWGM, Papapoulos SE, Verheijen J, Ponc M. Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts. *Journal of Investigative Dermatology* 1995; 104: 374-378.
- B105. Landman JO, Schweitzer DH, Frölich M, Hamdy NAT, Papapoulos SE. Recovery of serum calcium concentrations following acute hypocalcaemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate. *Journal of Clinical Endocrinology and Metabolism* 1995; 80: 524-528.
- B106. Denissen H, Kalk W, van Beek E, Löwik C, Papapoulos S, van den Hooff A. Composites of hydroxyapatite and bisphosphonate: properties and alveolar bone response. *Journal of Material Science; Materials in Medicine* 1995; 6: 35-40.
- B107. Schweitzer DH, Oostendorp-vd Ruit M, van der Pluijm G, Löwik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylamino-hydroxypropylidene bisphosphonate. *Journal of Bone and Mineral Research* 1995; 10:956-962.

- B108. Chou YHW, Pollak MR, Brandi ML, Toss G, Arnqvist H, Atkinson AB, Papapoulos SE, Marx S, Brown EM, Seidman JD, Seidman CE.
Mutations in the human calcium-sensing receptor gene that cause familial hypocalciuric hypercalcemia.
American Journal of Human Genetics 1995; 56: 1075-1079.
- B109. Schweitzer DH, Boxman ILA, Löwik CWGM, van Krieken JHJM, Weissglas MG, Baatenburg de Jong RJ, Papapoulos SE.
Parathyroid hormone-related protein and Interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients.
Journal of Clinical Pathology 1995; 48: 896-900.
- B110. van Beek E, Oostendorp-vd Ruit M, van der Wee-Pals L, Bloys H, van de Bent C, Papapoulos S, Löwik C.
Effects of experimental conditions on the release of ⁴⁵calcium from prelabelled fetal mouse long bones.
Bone 1995; 17: 63-69.
- B111. Most W, Schot L, Ederveen A, van der Wee-Pals L, Papapoulos S, Löwik C.
In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Journal of Bone and Mineral Research 1995; 10: 1523-1530.
- B112. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE.
Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
Journal of Clinical Endocrinology and Metabolism 1995; 80: 3465-3468.
- B113. Eggelmeijer F, Papapoulos SE, van Passen HC, Dijkmans BAC, Valkema R, Westedt ML, Landman JO, Pauwels EKJ, Breedveld FC.
Increased bone mass with pamidronate treatment in rheumatoid arthritis; results of a three-year randomized, double-blind trial.
Arthritis and Rheumatism 1996; 39: 396-402.
- B114. van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, Blijham G, Cleton FJ, van Eck-Smit BCF, Sleeboom HP, Papapoulos SE.
Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
European Journal of Cancer 1996; 32A: 450-454.
- B115. van der Pluijm G, Vloedgraven HJM, Ivanov B, Robey FA, Grzesik WJ, Gehron Robey P, Papapoulos SE, Löwik CWGM.
Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.
Cancer Research 1996; 56: 1948-1955.
- B116. Pelger RCM, Lycklama a Nijeholt AAb, Zwinderman AH, Papapoulos SE, Hamdy NAT.
The flare in serum alkaline phosphatase activity after orchidectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma.
Journal of Urology 1996; 155: 122-126.
- B117. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S.
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
Journal of Clinical Investigation 1996; 98: 698-705.
- B118. van Beek E, Löwik C, Que I, Papapoulos S.
Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

- Journal of Bone and Mineral Research* 1996; 11: 1492-1497.
- B119. Papapoulos SE, Lockefeer JHM.
Bisfosfonaten bij osteoporose; een herbeoordeling.
Nederlands Tijdschrift voor Geneeskunde 1996; 140:2394-2398.
- B120. Papapoulos SE, Frölich M.
Prediction of the outcome of treatment of Paget's disease of bone from short-term changes in the rate of bone resorption.
Journal of Clinical Endocrinology and Metabolism 1996; 81: 3993-3997.
- B121. Most W, van der Wee-Pals L, Ederveen A, Papapoulos S, Löwik C.
Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse.
Bone 1997; 20: 27-30.
- B122. van Beek E, Löwik CWGM, Papapoulos SE.
Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
Bone 1997; 20: 335-340.
- B123. Brumsen C, Hamdy NAT, Papapoulos SE.
Long-term effects of bisphosphonates on the growing skeleton; studies of young patients with severe osteoporosis.
Medicine 1997; 76: 266-283.
- B124. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJP, Papapoulos SE.
Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
European Journal of Pediatrics 1997; 156: 792-794.
- B125. Weissglas MG, Schamhart DHC, Löwik CWGM, Papapoulos SE, Theuns HM, Kurth KH.
The role of Interleukin-6 in the induction of hypercalcemia in renal cell carcinoma transplanted into nude mice.
Endocrinology 1997; 138: 1879-1885.
- B126. van der Pluijm G, Vloedgraven H, Papapoulos S, Löwik C, Grzesik W, Kerr J, Gehron-Robey P.
Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components.
Laboratory Investigation 1997; 77: 665-675.
- B127. Brown RJ, van Beek E, Watts DJ, Löwik CWGM, Papapoulos SE.
Differential effects of aminosubstituted analogs of hydroxybisphosphonates on the growth of *Dictyostelium discoideum*.
Journal of Bone and Mineral Research 1998; 13: 253-258.
- B128. van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik CWGM.
IL-1 α , IL-1 β , and TNF- α steady-state mRNA levels analysed by reverse transcription competitive PCR in bone marrow of gonadectomized mice.
Journal of Bone and Mineral Research 1998; 13: 185-194.
- B129. Pelger R, Hamdy NAT, Zwinderman AH, Lycklama a Nijeholt AAB, Papapoulos SE.
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
Bone 1998; 22: 403-408.
- B130. Goevaers CG, Leusink GL, Papapoulos SE, Maartens LW, Keyzer JJ, Weerdenburg JP, Beijers LM, Knottnerus JA, Pols HA, Pop VJ.
The prevalence of low bone mineral density in Dutch perimenopausal women; the Eindhoven Perimenopausal Study, EPOS.

- Osteoporosis International* 1998;8: 404-409.
- B131. van Bezooijen RI, Que I, Ederveen AGH, Kloosterboer HJ, Papapoulos SE, Löwik CWGM.
Plasma nitrate and nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats.
Journal of Endocrinology 1998, 159: 27-34.
- B132. Papapoulos SE.
Pharmacological management of osteoporosis.
Aging, Clinical and Experimental Research 1998; 10: 263-268 .
- B133. Compston JE, Papapoulos SE, Blanchard F. Report on osteoporosis in the European Community: Current status and recommendations for the future.
Osteoporosis International 1998; 8: 531-534.
- B134. van Beek ER, Lowik CWGM, Ebetino FH, Papapoulos SE.
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
Bone 1998; 23: 437-442.
- B135. Versluis RGJA, Petri H, van der Ven CM, Scholtes ABJ, Broerse ER, Springer MP, Papapoulos SE.
The usefulness of armspan and height comparison in detecting vertebral deformities in women.
Osteoporosis International 1999; 9: 129-133.
- B136. van Beek E, Löwik C, van der Pluijm G, Papapoulos SE.
The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates.
Journal of Bone and Mineral Research 1999; 14: 722-729.
- B137. Bravenboer N, Papapoulos SE, Holzman P, Hamdy NAT, Netelenbos JC, Lips P.
Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.
Osteoporosis International 1999; 9: 489-493.
- B138. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S.
Nitrogen-containing bisphosphonates inhibit Isopentenyl pyrophosphate isomerase/Farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.
Biochemical and Biophysical Research Communications 1999; 255: 491-494.
- B139. van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik CWGM.
Interleukin-17: A new bone acting cytokine in vitro.
Journal of Bone and Mineral Research 1999;14: 1513-1521.
- B140. Versluis RGJA, Petri H, van de Ven CM, Scholtes ABJ, Papapoulos SE, Springer MP.
Prevalentie van osteoporose bij postmenopausale vrouwen in een huisartspraktijk.
Nederlands Tijdschrift voor Geneeskunde 1999; 43: 20-24.
- B141. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos SE, Rizzoli R, Seeman E, Wasnich RD.
Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines.
Clinical Therapeutics 1999; 21: 1025-1044.
- B142. van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S.
Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
Biochemical Biophysical Research Communications 1999;264: 108-111.

- B143. Karperien M, van der Harten HJ, van Schooten R, Farih-Sips H, den Hollander NS, Kneppers SLJ, Nijweide P, Papapoulos SE, Löwik CWGM.
A frame-shift mutation in the type I parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand lethal osteochondrodysplasia.
Journal of Clinical Endocrinology and Metabolism 1999; 84: 3713-3720.
- B144. Karperien M, Farih-Sips H, Hendriks JAA, Lanske B, Papapoulos SE, Abou-Samra AB, Löwik CWGM, Defize LHK.
Identification of a retinoic acid-inducible element in murine PTH/PTHrP (Parathyroid hormone/Parathyroid hormone-related peptide) receptor gene.
Molecular Endocrinology 1999; 13: 1183-1196.
- B145. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BEC, Barret-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Eis SR, Gennari C, Johnell O, Johnston CC, Lau EMC, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Miller PD, Mithal A, Morii H, Papapoulos S, Woolf A, Yu W, Khaltayev N.
Interim report and recommendations of the World Health Organization task-force for osteoporosis.
Osteoporosis International 1999; 10: 259-264.
- B146. van Bezooijen RL, van der Bent C, Papapoulos SE, Löwik CWGM.
Oestrogenic compounds modulate cytokine-induced nitric oxide production in mouse osteoblast-like cells.
Journal of Pharmacy and Pharmacology 1999; 51: 1409-1414.
- B147. Laitala-Leinonen T, Löwik C, Papapoulos S, Väänänen HK.
Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro.
Journal of Cell Science 1999; 112: 3657-3666
- B148. van der Pluijm G, Löwik C, Papapoulos S.
Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem.
Cancer Treatment Reviews 2000; 26: 11-27.
- B149. Versluis RGJA, Petri H, Vismans FJFE, van de Ven CM, Springer MP, Papapoulos SE.
The relationship between phalangeal bone density and vertebral deformities.
Calcified Tissue International 2000; 66: 1-4.
- B150. Papapoulos SE, Hamdy NAT, van der Pluijm G.
Bisphosphonates in the management of prostate cancer metastatic to the skeleton.
Cancer 2000; 88: 3047-53
- B151. Deckers MML, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Löwik CWGM.
Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation.
Endocrinology 2000; 141: 1667-1674.
- B152. Papapoulos SE.
Bisphosphonates in the treatment of osteoporosis ; principles and efficacy.
Annales Medicin Interne 2000; 151: 504-510.
- B153. Hamdy NAT, Papapoulos SE.
The palliative management of skeletal metastases in prostate cancer : use of bone-seeking radionuclides and bisphosphonates.
Seminars in Nuclear Medicine 2001; 31: 62-68.
- B154. van Bezooijen R, Papapoulos SE, Löwik CWGM.

- Effect of IL-17 on nitric oxide production and osteoclastic bone resorption; dependency on NF- κ B and RANK/RANKL signaling?
Bone 2001;28: 378-386.
- B155. Deckers M, van der Pluim G, Dooijewaard S, Kroon M, van Hinsbergh V, Papapoulos S, Löwik C.
Effect of angiogenic and anti-angiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants.
Laboratory Investigation 2001; 81: 5-15.
- B156. Van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Löwik C.
Monitoring metastatic behavior in human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
Journal of Bone and Mineral Research 2001; 16 : 1077-1091.
- B157. Papapoulos SE.
Catabolic and anabolic signals in bone : therapeutic implications.
Current Opinion in Clinical Nutrition and Metabolic Care 2001; 4: 191-196.
- B158. van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C.
Urokinase-receptor/integrin complexes are functionally involved in adhesion progression of human breast cancer in vivo.
American Journal of Pathology 2001; 159: 971-982.
- B159. Versluis RGJA, Papapoulos SE, de Bock GH, Zwinderman AH, Petri H, van de Ven CM, Springer MP.
Clinical risk factors as predictors of postmenopausal osteoporosis in general practice.
British Journal of General Practice 2001; 51: 806-810.
- B.160. Schell-Feith EA, Que I, Kok DJ, Kist-van Holthe JE, Kuhler R, Brand R, Papapoulos SE, van der Heijden BJ.
Modulation of calcium oxalate monohydrate crystallization kinetics by urine of preterm neonates.
American Journal of Kidney Diseases 2001; 38: 1229-1234.
- B161. van Beek E, Lowik C, Papapoulos S.
Bisphosphonates suppress bone resorption by a direct effect on osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of geranylgeranylation in the action of N-BPs on osteoclast precursors.
Bone 2002; 30: 64-70
- B162. Dang ZC, van Bezooijen RL, Karperien M, Papapoulos S, Lowik C.
Exposure of KS483 cells to estrogens enhances osteogenesis and inhibits adipogenesis.
Journal of Bone and Mineral Research 2002; 17: 394-405.
- B163. Cremers S, Sparidans R, den Hartigh J, Hamdy N, Vermeij P, Papapoulos S.
A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis.
European Journal of Clinical Pharmacology 2002; 57: 883-890.
- B164. Brumsen C, Hamdy NAT, Papapoulos SE.
Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy.

- Journal of Bone and Mineral Research* 2002; 17: 567-569.
- B165. Soerdjbalie-Maikoe V, Pelger RCM, Lycklama a Nijholt GAB, Arndt J-W, Zwinderman AH, Papapoulos SE, Hamdy NAT.
Strontium-89 (Mestranon) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
European Journal of Nuclear Medicine 2002; 29: 494-498.
- B166. Deckers ML, van Bezooijen RL, van der Horst G, Hoogendam J, van der Bent C, Papapoulos SE, Lowik CWGM.
BMPs stimulate angiogenesis through osteoblast-derived VEGF-A.
Endocrinology 2002; 143: 1545-1553.
- B167. Deckers MML, van Beek ER, van der Pluijm G, Wetterwald A, van der Wee-Pals L, Cecchini MG, Papapoulos SE, Lowik CWGM.
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice.
Journal of Bone and Mineral Research 2002; 17: 998-1007.
- B168. Staehling-Hampton K, Proll S, Paepers BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME.
A 52 kb deletion in the *SOST-MEOXI* intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
American Journal of Medical Genetics 2002; 110: 144-152.
- B169. Hamdy NAT, Papapoulos SE.
Management of malignancy-associated hypercalcaemia.
Clinical Reviews in Bone and Mineral Metabolism 2002; 1: 65-76.
- B170. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EKJ, Roos JC, Valentijn RM, Zwinderman AH.
Daily oral pamidronate in women and men with osteoporosis; a three-year randomized, placebo-controlled clinical trial with a two-year open extension.
Journal of Bone and Mineral Research 2002; 17: 1057-1064.
- B171. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, Delmas P, Eisman J, Johnell O, Johnsson B, Melton L, Oden A, Papapoulos S, Pols H, Rizzoli R, Silman A, Tenenhouse A.
A new approach to the development of assessment guidelines for osteoporosis.
Osteoporosis International 2002; 13: 527-536.
- B172. van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Lowik CW.
Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.
Annals Rheumatic Diseases 2002; 61: 870-876.
- B173. Papapoulos SE.
Pharmacological management of Paget's disease of bone.
Clinical Reviews in Bone and Mineral Metabolism 2002; 1: 149-158.
- B174. Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NAT.

- A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men.
Bone 2002; 31: 556-561.
- B175. van de Horst G, van Bezooijen RL, Deckers MML, Visser A, Farih-Sips HCM, Papapoulos SE, Löwik CWGM, Karperien M. Differentiation of murine pre-osteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation.
Bone 2002 31(6): 661-669.
- B176. Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CWGM.
Peroxisome Proliferator-activator Receptor gamma (PPAR γ) is a molecular target for the soy phytoestrogen genistein.
Journal of Biological Chemistry 2003; 278: 962-967.
- B177. Cremers SCLM, Eekhoff MEMW, den Hartigh J, Vermeij P, Papapoulos SE.
Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Journal of Bone and Mineral Research 2003; 18: 868-875.
- B178. Eekhoff EMW, Zwinderman AH, Haverkort DMAD, Cremers SCLM, Hamdy NAT, Papapoulos SE.
Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
Bone 2003; 33: 831-838.
- B179. van der Pluijm G, Deckers M, Sijmpns B, de Groot H, Bird J, Wills R, Papapoulos S, Baxter A, Lowik C.
In vitro and in vivo endochondral bone formation models allow identification of anti-angiogenic compounds.
American Journal of Pathology 2003; 163: 157-163.
- B180. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CWGM, Papapoulos SE.
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
Bone 2003; 33: 805-811.
- B181. Papapoulos SE.
Ibandronate: a new potent bisphosphonate for the management of osteoporosis.
International Journal of Clinical Practice 2003; 57: 417-422.
- B182. Eekhoff EWM, van der Klift M, Kroon HM, Cooper C, Hofman A, Pols HAP, Papapoulos SE.
Paget's disease of bone in the Netherlands: a population-based radiological and biochemical survey; the Rotterdam study.
Journal of Bone and Mineral Research 2004; 19: 566-570.
- B183. van Bezooijen RL, Roelen BAJ, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CWGM.
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
Journal of Experimental Medicine 2004; 199: 805-814
- B184. Eekhoff EWM, Karperien M, Houtsma D, Zwinderman AH, Dragoiescu C, Kneppers ALJ, Papapoulos SE.

- Familial Paget's disease in the Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene and their clinical association.
Arthritis and Rheumatism 2004; 50:1650-1654.
- B185. Soerdijbalie-Maikoe V, Pelger RCM, Lycklama a Nijeholt GAB, Arndt J-W, Zwinderman AH, Bril H, Papapoulos SE, Hamdy NA.
Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.
European Journal of Nuclear Medicine and Molecular Imaging 2004; 31:958-963.
- B186. Buijs JT, Cleton AM, Smit VT, Lowik CW, Papapoulos S, vd Pluijm G.
Prognostic significance of periodic acid Schiff-positive pattern in primary breast cancer and its lymph node metastases.
Breast Cancer Research and Treatment 2004; 84: 117-130.
- B187. Cremers SCLM, Lodder MC, den Hartigh J, Vermeij P, van Pelt PA, Lems WF, Papapoulos SE, Dijkmans BAC.
Short-term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
Journal of Rheumatology 2004; 31: 1732-1737.
- B188. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE.
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women.
Osteoporosis International 2005; 16: 468-474.
- B189. Cremers SCLM, Pillai G, Papapoulos SE.
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis.
Clinical Pharmacokinetics 2005; 44: 551-570.
- B190. Pelger RCM, Lycklama a Nijeholt GAB, Papapoulos SE, Hamdy NAT.
Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.
Bone 2005; 36:1-5
- B191. Sanders JM, Song Y, Chan JMW, Zhang Y, Jennings S, Kostowski T, Odeh S, Flassner R, Schwerdtfeger C, Kotsikorou E, Meints GA, Gomez AO, Gonzales-Pacanowska D, Raker AM, wang H, van Beek ER, Papapoulos SE, Moritsa GT, Oldfield E.
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Journal of Medicinal Chemistry 2005; 48:2957-2963.
- B192. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowick CWGM.
SOST\sclerostin, an osteocyte-derived negative regulator of bone formation.
Cytokine & Growth Factor Reviews 2005; 16: 319-327.
- B193. van Bezooijen RL, Papapoulos SE, Lowick CWGM.
Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
Journal of Endocrinological Investigation 2005; 25 (suppl 8): 15-17.
- B 194. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE.
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis.

- Bone* 2005; 37: 651-654..
- B195. Cremers SCLM, van Hogezaand R, Banffer D, den Hartigh J, Vermeij P, Papapoulos SE, Hamdy NAT.
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease.
Osteoporosis International 2005; 16: 1727-1730.
- B196. Cremers SCLM, Papapoulos SE, Gelderblom H, Seynaeve C, den Hartigh J, Vermeij P, van der Rijt CCD, van Zuylen C.
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Journal of Bone and Mineral Research 2005; 20:1543-1547.
- B197. Poole KES, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J.
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
FASEB Journal 2005; 19: 1842-44.
- B198. van der Pluim G, Que I, Sijmons B, Buijs JT, Lowik CWGM, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG.
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.
Cancer Research 2005; 65: 7682-7690.
- B199. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NAT, Löwik CWGM, Hamersma H, Beighton P, Papapoulos SE.
Bone mineral density in sclerosteosis; affected individuals and gene carriers.
Journal of Clinical Endocrinology and Metabolism 2005; 90:6392-5.
- B200. Papapoulos SE.
Who will benefit from antiresorptive treatment (bisphosphonates)?
Best Practice and Research Clinical Rheumatology 2005; 19:965-973.
- B201. van Beek E, Lowik C, Karperien M, Papapoulos S.
Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: The role of retinoic acid receptor.
Bone 2006; 38:167-171.
- B202. Papapoulos SE
Bisphosphonate actions: Physical chemistry revisited.
Bone 2006; 38: 613-616.
- B203. Papapoulos SE
Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease? (commentary)
Nature Clinical Practice Endocrinology & Metabolism 2006; 2: 252-253.
- B204. Papapoulos SE, Eekhoff EMW, Zwinderman AH
Acquired resistance to bisphosphonates in Paget's disease of bone.
Journal of Bone and Mineral Research 2006; 21 (suppl 2): 88-91.
- B205. van Bezooijen R, Svensson PJ, Eefting D, Visser A, van der Horst G, Karperien M, Quax P, Vriendeling H, Papapoulos SE, ten Dijke P, Lowik CW.

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

Journal of Bone and Mineral Research 2007; 22: 19-28.

- B206. van Bezooijen RL, DeRuiter MC, Vilain N, Monteiro RM, Visser A, van der Wee-Pals L, Hogendoorn PCW, Aguet M, Mummery CL, Papapoulos SE, ten Dijke P, Lowik CWGM. SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development.
Developmental Dynamics 2007; 236: 606-612.
- B207. Papapoulos SE, Cremers SCLM
Prolonged bisphosphonate release after treatment in children..
New England Journal of Medicine 2007; 356: 1075-76.
- B208. Papapoulos SE, Schimmer RC.
Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Annals of Rheumatic Diseases 2007; 66:853-858.
- B209. Weissglas M, Lowik C, Schamhardt D, Theuns H, Kurth K-H, Papapoulos S. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
BJU International 2007; 99:1530-33.
- B210. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Lowik CW, van der Pluijm G.
BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo.
American Journal of Pathology 2007; 171: 1047-57.
- B211. Buis JT, Hendriquez NV, van Overveld PGM, van der Horst G, Que I, Schwaninger R, Rentsch C, ten Dijke P, Cleton-Jansen A-M, Driouch K, Ledereau R, Bachelier R, Vukicevic S, Clezardin P, Papapoulos SE, Cecchini M, Lowik CWGM, van der Pluijm G.
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Cancer Research 2007; 67: 8742-51.
- B212. Papapoulos SE.
Determinants of bone strength in clinical practice; effects of bisphosphonates.
Bone 2007; 41 (Suppl 1): S3-S7.
- B213. Bauss F, Pfister T, Papapoulos S.
Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.
Journal of Bone and Mineral Metabolism 2008 ; 26: 406-408.
- B214. Rizzoli R, Burllet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster J-Y.
The risk of developing osteonecrosis of the jaw in patients with osteoporosis treated with bisphosphonates: a report from ESCEO.
Bone 2008; 42: 841-847.
- B215. Makras P, Hamdy NAT, Kant SG, Papapoulos SE.
Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.
Journal of Clinical Endocrinology & Metabolism 2008; 93: 1386-1389.

- B216. Roux C, Bischoff-Ferrari HE, Papapoulos SE, de Papp AE, West JA, Bouillon R. New insights into the role of vitamin D and calcium in osteoporosis management: An expert round table discussion.
Current Medical Research and Opinion 2008; 24: 1363-1370.
- B217. Papapoulos S, Makras P. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis.
Nature Clinical Practice Endocrinology & Metabolism 2008; 4: 514-523.
- B218. Papapoulos SE, Schimmer RC. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.
Postgraduate Medical Journal 2008; 84: 307-312.
- B219. Chung PY, Beyens G, Gunaabens N, Boonen S, Papapoulos S, Karperien M, Eekhoff M, Van Wesenbeeck L, Jennes K, Geusens P, Offeciers E, Van Offel J, Westhovens R, Zmierzczak H, Devogelaer JP, Van Hul W. Founder Effect in Different European Countries for the Recurrent P392L SQSTM1 Mutation in Paget's Disease of Bone.
Calcified Tissue International 2008 ; 83: 34-42.
- B220. Papapoulos SE. Bisphosphonates: How do they work?
Best Clinical Endocrinology & Metabolism 2008; 22: 831-847.
- B221. Cranney A, Wells G, Yetisir L, Adami S, Cooper C, Delmas P, Miller P, Papapoulos S, Reginster J-Y, Sambrook P, Silverman S, Siris E, Adachi J. Ibandronate for the prevention of non-vertebral fractures: A pooled analysis of individual patient data.
Osteoporosis International 2009; 20: 291-297.
- B222. Buijs JT, Que I, Lowik CW, Papapoulos SE, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Bone 2009; 44: 380-386.
- B223. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, Heaney R, Seeman E, Papapoulos S, Goldring SR. Targeting bone remodeling for the treatment of osteoporosis: Summary of the proceedings of an ASBMR workshop.
Journal of Bone and Mineral Research 2009; 24: 373-385..
- B224. Netelenbos CJ, Iems W, Geusens PP, Verhaar HJ, Boomsma M, Mulder PGH, Papapoulos SE. Spine radiographs to improve the identification of women at high risk of fractures.
Osteoporosis International 2009; 20: 1347-52.
- B225. van Beek ER, Lowik CW, van Wijngaarden J, Ebetino FH, Papapoulos S. Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease.
Breast Cancer Research and Treatment 2009; 118:307-313.
- B226. Makras P, Hamdy NA, Ballieux BE, Zwinderman KH, Papapoulos SE. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Bone 2009; 44: 766-771.
- B227. van Bezooijen RL, Bronckers LA, Gortzak RA, Hogendoorn PCW, van der Wee-Pals L, Balemans W, Oostenbroek HJ, Van Hul W, Hamersma H, Dikkers FG, Hamdy NAT, Papapoulos SE, Löwik CWGM. Sclerostin in Mineralized Matrices and Van Buchem Disease.
Journal of Dental Research 2009; 88:569-74.

- B228. Zhang Y, Cao R, Yin F, Hudock M, Guo R-T, Krysiak K, Mukherjee S, Gao YG, Robinson H, Song Y, No J-H, Bergan K, Leon A, Cass L, Gaddara A, Chang T-K, van Beek E, Papapoulos S, Wang A, Kubo T, Ochi M, Mukkamala D, Oldfield E. Lipophilic bisphosphonates as farnesyl/geranylgeranyl diphosphate synthase inhibitors: an x-ray and NMR investigation.
Journal of the American Chemical Society 2009; 131: 5135-5162.
- B229. Somford MP, Draijer FW, Thomassen BJW, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
Journal of Bone and Mineral Research 2009; 24: 1736-1740.
- B230. Makras P, Papapoulos SE. Medical treatment of hypercalcaemia.
Hormones 2009; 8:83-95.
- B231. Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.
International Journal of Clinical Practice. 2010; 64: 821-826.
- B232. Power J, Poole KE, van Bezooijen R, Doube M, Caballero-Alfás AM, Lowik C, Papapoulos S, Reeve J, Loveridge N. Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture.
Journal of Bone and Mineral Research 2010;25:569-574
- B233. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: Current knowledge and future perspectives.
Calcified Tissue International 2010; 87: 99-107.
- B234. PETERS E, Culha C, Moester M, Van Bezooijen R, Adriaensen D, Mueller T, Weidauer S, Jennes K, de Freitas F, Löwik C, Timmermans JP, Van Hul W, Papapoulos S. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
Human Mutation 2010 ;31:E1526-E1543.
- B235. van Lierop A, Hamdy NAT, Papapoulos SE. Glucocorticoids are not always deleterious for bone.
Journal of Bone and Mineral Research 2010; 25: 2520-2524.
- B236. Giusti A, Hamdy NAT, Papapoulos SE. Atypical fractures of the femur and use of bisphosphonates: A systematic review of cases/case studies.
Bone 2010; 47:169-180.
- B237. Chung PY, Beyens G, Riches PL, Van Wesenbeeck L, de Freitas F, Jennes K, Daroszewska A, Franssen E, Boonen S, Geusens P, Vanhoenacker F, Verbruggen L, Van Offel J, Goemaere S, Zmierzak HG, Westhovens R, Karperien M, Papapoulos S, Ralston SH, Devogelaer JP, Van Hul W. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone.
Journal of Bone and Mineral Research 2010; 25: 2316-2329.
- B238. van Lierop AH, Witteveen J, Hamdy N, Papapoulos S. Patients with Primary Hyperparathyroidism Have Lower Circulating Sclerostin Levels than Euparathyroid Controls.
European Journal of Endocrinology 2010; 163: 833-7.

- B239. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. *Journal of Bone and Mineral Research* 2010; 25: 2267-2294.
- B240. Chung PY, Beyens G, Boonen S, Papapoulos S, Geusens P, Karperien M, Vanhoenacker F, Verbruggen L, Franssen E, Van Offel J, Goemaere S, Zmierzczak HG, Westhovens R, Devogelaer JP, Van Hul W. The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. *Human Genetics* 2010; 28:615-626.
- B241. Yavropoulou MP, Papapoulos SE. Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis. *Expert Reviews in Endocrinology & Metabolism* 2010; 5:711-722.
- B242. The ESHRE Capri Workshop Group. Bone fractures after menopause. *Human Reproduction Update* 2010; 16: 761-773.
- B243. Papapoulos SE. Use of bisphosphonates in the management of postmenopausal osteoporosis. *Annals New York Academy of Science* 2011; 22:373-390.
- B244. Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. *Osteoporosis International* 2011; 22:373-390.
- B245. Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fractures with radiographic adjudication of fracture site and features. *Bone* 2011; 48:966-971.
- B246. Makras P, Anastasilakis AD, Polyzos SA, Bisbinas I, Sakellariou GT, Papapoulos SE. No effect of rosuvastatin in the zoledronate-induced acute-phase response. *Calcified Tissue International* 2011; 88:402-408.
- B247. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. *Bone* 2011; 49:42-49.
- B248. Papapoulos SE. Targeting sclerostin as potential treatment of osteoporosis. *Annals of Rheumatic Diseases* 2011; 70 (suppl 1); i119-22.
- B249. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and markers of bone turnover in postmenopausal women with low bone mineral density. *Journal of Clinical Endocrinology and Metabolism* 2011; 96:2441-2449.
- B250. Albagha OME, Wani S, Visconti MR, Alonson N, Goodman K, Brandi ML, Cundy T, Chung PYJ, Dargie R, Devogelaer J-P, Falchetti A, Fraser WD, Gennari L,

- Gianfrancesco F, Hooper MJ, van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, Montes JD, Ratajczak T, Rea SL, Rendina D, Gonzales-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH.
Genome-wide association identifies three new susceptibility loci for Paget's disease of bone.
Nature Genetics 2011; 43:685-689.
- B251. Van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE.
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
Journal of Bone and Mineral Research 2011; 26: 2804-811.
- B252. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV.
Interpretation and use of FRAX in clinical practice.
Osteoporosis International 2011; 22:2395-411.
- B253. Papapoulos SE.
Bisphosphonate therapy in children with secondary osteoporosis.
Hormone Research Paediatrics 2011; 76(suppl 1): 24-27.
- B254. Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey M, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R; FRAX Position Development Conference Members.
Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX; Executive Summary of the 2010 Position Development Conference on interpretation and use of FRAX in clinical practice.
Journal of Clinical Densitometry 2011; 14: 171-180.
- B255. Yavropoulou M, Papapoulos SE.
Sex hormone deprivation and bone metabolism in cancer patients
Bone 2011; 48: S26-S32
- B256. van Lierop AH, Hamdy NAT, van Bezooijen RL, Lowik CW, Papapoulos SE.
The role of sclerostin in the pathophysiology of bone sclerosing dysplasias.
Clinical Reviews in Bone and Mineral Metabolism 2012; 10:108-116
- B257. Barrett-Connor E, Swern AS, Hustad CM, Bone HG, Liberman UA, Papapoulos SE, Wang H, de Papp A, Santora AC.
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
Osteoporosis International 2012; 23: 233-245.
- B258. Witteveen J, van Lierop AH, Papapoulos S, Hamdy N.
Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?
European Journal of Endocrinology 2012; 166:55-60
- B259. S Papapoulos, R Chapurlat, C Libanati, ML Brandi, JP Brown, E Czerwiński, M-A Krieg, Z Man, D Mellström, SC Radominski, J-Y Reginster, H Resch, JA Román, C Roux, E Vittinghoff, M Austin, N Daizadeh, MN Bradley, A Grauer, SR Cummings, HG Bone.
Five Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension.
Journal of Bone and Mineral Research 2012; 27: 694-701.

- B260. Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S
Inhibition of cathepsin K for treatment of osteoporosis.
Current Osteoporosis Reports 2012; 10:73-79
- B261. van Lierop AH, Hamdy NAT, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk
Diamant M, Romijn JA, JWA Smit JWA, Papapoulos SE
Distinct effects of pioglitazone and metformin on circulating sclerostin and
biochemical markers of bone turnover in men with Type 2 Diabetes Mellitus.
European Journal of Endocrinology 2012; 166:711-716.
- B262. Anastasilakis AD, Polyzos SA, Makras P, Sakellariou GT, Bisbinas I, Gkiomisi A,
Delaroudis S, Gerou S, Ballaouri I, Oikonomou D, Papapoulos SE.
Acute phase response following intravenous zoledronate in postmenopausal
women with low bone mass.
Bone 2012; 50:1130-1134.
- B263. Yavropoulou MP, Giusti A, Ramautar SR, Dijkstra S, Hamdy NA, Papapoulos SE.
Low-energy fractures of the humeral shaft and bisphosphonate use.
Journal of Bone and Mineral Research 2012; 27:1425-1431.
- B264. Goldhahn J, Féron JM, Kanis J, Papapoulos S, Reginster JY, Rizzoli R, Dere W,
Mitslak B, Tsouderos Y, Boonen S.
Implications for Fracture Healing of Current and New Osteoporosis Treatments:
An ESCEO Consensus Paper.
Calcified Tissue International 2012; 90:343-353.
- B265. van Egmond ME, Dikkers FG, Boot AM, van Lierop AH, Papapoulos SE,
Brouwer OF.
A rare cause of facial nerve palsy in children: Hyperostosis corticalis generalisata
(Van Buchem disease). Three new pediatric cases and a literature review.
European Journal of Paediatric Neurology 2012; 16:740-743
- B266. Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE.
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases
with a wide range of bone turnover.
Bone 2012; 51: 153-157.
- B267. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M,
Papapoulos SE.
Circulating sclerostin levels are decreased in patients with endogenous
hypercortisolism and increase after treatment.
Journal of Clinical Endocrinology and Metabolism 2012; 97: E1953-E1957.
- B268. Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA,
Laslop A, Mitslak B, Papapoulos S, Ralston S, Reiter S, Werhaya G, Reginster JY
Management of Glucocorticoid-Induced Osteoporosis.
Calcified Tissue International 2012; 91:225-243.
- B269. van Lierop A, Hamdy N, van Egmond M, Bakker E, Dikkers F, Papapoulos S.
Van Buchem disease: Clinical, biochemical and densitometric features of patients and
disease carriers.
Journal of Bone and Mineral Research 2013; 28:848-854.
- B270. Yavropoulou MP, Hamdy NAT, Papapoulos SE.
Long-term Treatment of Osteoporotic Women with Bisphosphonates does not Impair
the Response to Subsequently Administered Intravenous Pamidronate.
Osteoporosis International 2013; 24:2353-7.

- B271. Papapoulos SE.
Bisphosphonates in osteoporosis – beyond 5 years
Nature Reviews of Rheumatology 2013; 9: 263-4.
- B272. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwiński E, Krieg M-A, Man Z, Mellström D, Radominski SC, Reginster J-Y, Resch H, Román Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S.
The Effect of 3 or 6 Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension.
Journal of Clinical Endocrinology & Metabolism 2013; 98: 4483-92.
- B273. Durosier C, Van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R.
Association of Circulating Sclerostin with Bone Mineral Mass, Microstructure, and Turnover in Healthy Elderly Men and Women.
Journal of Clinical Endocrinology & Metabolism 2013; 98: 3873-83.
- B274. Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Papapoulos S, Kanis JA.
Epidemiology and Economic Burden of Osteoporosis in the Netherlands.
Archives of Osteoporosis 2013; 8: 137 pp 146-153.
- B275. Appelman-Dijkstra NM, Papapoulos SE.
Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches.
Best Practice & Research Clinical Rheumatology 2013; 27: 805-820.
- B276. Shane E, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Tetsen H, van der Meulen MC, Weinstein RS, Whyte MP.
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research.
Journal of Bone and Mineral Research 2014; 29:1-23.
- B277. van Lierop A, Moester M, Hamdy N, Papapoulos S.
Serum Dickkopf 1 Levels in Sclerostin Deficiency.
Journal of Clinical Endocrinology & Metabolism 2014; 99:E252-E256.
- B278. Hassler N, Roschger A, Gamsjaeger S, Kramer A., Lueger S, van Lierop A, Roschger P, Klaushofer K, Paschalis EP, Kneissel M, Papapoulos S.
Sclerostin deficiency linked to altered bone composition.
Journal of Bone and Mineral Research 2014; 29:2144-.
- B279. Papapoulos SE.
Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations.
BoneKEy Reports 2014; 3, 523.
- B280. Kanis JA, McCloskey E, Branco J, Brandi ML, Dennison E, Devogelaer JP, Ferrari S, Kaufman JM, Papapoulos S, Reginster JY, Rizzoli R.
Goal-directed treatment of osteoporosis in Europe.
Osteoporosis International 2014; 25: 2533-43.

- B281. Appelman-Dijkstra NM, Papapoulos SE
Novel approaches to the treatment of osteoporosis
Best Practice & Research Clinical Endocrinology & Metabolism 2014; 28: 843-857.
- B282. Papapoulos S.
In memoriam Olav Bijvoet.
Bone 2014; 68:167-168.
- B283. Bone H, Dempster D, Eisman JA, Greenspan SL, McClung M, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora A, Verbruggen, Leung AT, Lombardi A
Odanacatib for the Treatment of Postmenopausal Osteoporosis: Development History and Design and Participant Characteristics of LOFT, the Long-term Odanacatib Fracture Trial
Osteoporosis International 2015; 26:699-712.
- B284. Papapoulos SE.
Anabolic bone therapies 2014: New bone-forming treatments for osteoporosis.
Nature Reviews of Endocrinology 2015; 11: 69-70.
- B285. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM.
Bone Material Strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of Bone Mineral Density.
Journal of Clinical Endocrinology & Metabolism 2015; 100:2039-2045.
- B286. Appelman-Dijkstra NM, Papapoulos SE.
Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis.
Drugs 2015; 75:1049-1058.
- B287. L. Masi, D. Agnusdei, J. Bilezikian, D. Chappard, R. Chapurlat, L. Cianferotti, J-P. Devolgelaer, A. El Maghraoui, S. Ferrari, F. Jakob, K. Javaid, J-M. Kaufman, U.A. Liberman, G. Lyritis, P. Miller, N. Napoli, E. Roldan -co-opted member, S. Papapoulos, N.B. Watts, M.L. Brandi.
Taxonomy of Rare Genetic Metabolic Bone Disorders.
Osteoporosis International 2015; 26:2529-58.
- B288. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG.
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Osteoporosis International 2015; 26: 2773-2783.
- B289. Thijs W, Janssen K, van Schadewijk AM, Papapoulos SE, Cessie S, Middeldorp S, Melissant CF, Rabe KF, Hiemstra PS.
Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH)₂ Vitamin D₃ Treatment.
PLoS One 2015;10(11):e0140986.
- B290. Appelman-Dijkstra NM, Papapoulos SE.
From Disease to Treatment: From rare skeletal disorders to treatments for osteoporosis.

- Endocrine* 2016; 52:414-426.
- B291. Appelman-Dijkstra NM, Papapoulos SE.
Sclerostin inhibition in the management of osteoporosis.
Calcified Tissue International 2016; 98:370-380.
- B292. Papapoulos SE.
Romosozumab – getting there but not quite yet.
Nature Reviews Endocrinology 2016; 12:691-2.
- B293. Diez-Perez A, Bouxsein ML, Eriksen EF, Khosla S, Nyman JS, Papapoulos S, Tang SY
Technical note: Recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation.
Bone Reports 2016; 5: 181-5.
- B294. van Lierop A, Appelman-Dijkstra NM, Papapoulos SE.
Human sclerostin deficiency.
Bone 2017; 96:51-62.
- B295. Robling AG, Drake MT, Papapoulos SE.
Sclerostin: from bedside to bench and back to bedside.
Bone 2017; 96:1-2.
- B296. Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG.
Safety observations with three years of denosumab exposure. Comparison between subjects who received denosumab during FREEDOM and subjects who crossed over to denosumab during FREEDOM extension.
Journal of Bone & Mineral Research 2017; 32:1481-1485
- B297. Anastasilakis AD, Yavropoulou MP, Makras P, Sakellatou GT, Papadopoulou F, Gerou S, Papapoulos SE. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
European Journal of Endocrinology 2017; 176:677-683
- B298. Bone HG, Wagman RB, Brandi ML, Jacques P, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Astrid Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster J-Y, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S.
Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the Phase 3 Randomized FREEDOM Trial and the Open-label Extension
Lancet Diabetes & Endocrinology 2017; 5:513-523
- B299. Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskeletal Disorders 2017; 18:174.
- B300. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM.
Bone Material Strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site.
Osteoporosis International 2017; 28:2433-2437.

- B301. Malgo F, Hamdy NAT, Papapoulos SE, Appelman-Dijkstra NM.
Impact microindentation: Consistency of serial measurements and alterations in patients with Paget's disease of the tibia.
Journal of Bone & Mineral Research 2017; 32:2375-2380

C. ARTICLES IN PROCEEDINGS

- C1. Junor BJR, Catto CRD, MacLeod M, Papapoulos SE, O’Riordan JLH, Fraser RA.
1 α -hydroxycholecalciferol in the treatment of renal osteodystrophy.
Proceedings EDTA 1977; 13: 424-433.
- C2. Papapoulos SE, Brownjohn AM, Goodwin FJ, Hately W, Marsh FP, O’Riordan JLH.
The effect of 1 α -hydroxycholecalciferol on secondary hyperparathyroidism of chronic renal failure.
In: Norman AW et al eds. *Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism*. Berlin: Walter de Gruyter 1977: 693-695.
- C3. O’Riordan JLH, Clemens TL, Hendy GN, Fraher LJ, Sandler LM, Papapoulos SE.
Radioimmunoassay for circulating 1,25- and 25,26-dihydroxycholecalciferol in man.
In: Norman AW et al eds. *Vitamin D: Basic Research and its Clinical Application*. Berlin: Walter de Gruyter 1979: 289-295.
- C4. Care AD, Pickard DW, Papapoulos SE, O’Riordan JLH, Garel M, Redel J.
The interactions between vitamin D metabolites, parathyroid hormone and calcitonin.
In: Norman AW et al eds. *Vitamin D: Basic Research and its Clinical Application*. Berlin: Walter de Gruyter 1979: 289-295.
- C5. O’Riordan JLH, Hendy GN, Fraher LJ, Papapoulos SE, Sandler LM, Clemens TL.
Development and clinical application of a radioimmunoassay for circulating 1,25- and 25,26-dihydroxycholecalciferol in man.
In: Bizollon ChA ed. *Radioimmunology 1979*. Amsterdam: Elsevier 1979: 161-170.
- C6. Muirhead N, Catto CRD, Edward N, Fraser RA, O’Riordan JLH, Papapoulos SE, Adami S.
Comparison of 1,25-(OH)₂D₃ and 24,25-(OH)₂D₃ in the long-term treatment of renal osteodystrophy.
Proceedings EDTA 1980; 17: 543-547.
- C7. Papapoulos SE, Mortoglou AA, Saridaki C, Poulantzas N, Thomopoulou H.
The effect of exogenous parathyroid hormone on circulating prolactin in normal, hypoparathyroid and hypopituitary man.
Acta Endocrinologica 1983; 261s: 30-31.

- C8. Sharman VL, Abrams SM, Adami S, Cattell WR, Greenwood RN, Goodwin FJ, Hately W, Hattersly LA, Marsh FP, Morgan AG, Muir JW, O'Riordan JL, Papapoulos SE, Revell P, Tacker AK, Baker LR.
Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients.
Proceedings EDTA 1983; 19: 287-292.
- C9. Papapoulos S.
Vitamin D and metabolic bone disease in gastrointestinal and hepatic disorders.
In: Griffioen G, Janssens AR, Kreuning J, Verspaget HW eds. *Maag-, darm en leverziekten 1985*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde 1985: 25-30.
- C10. Kok DJ, Papapoulos SE, Bijvoet OLM.
Defective or absent inhibition of agglomeration in the presence of normal inhibition of crystal growth in stone-formers with a high recurrence rate.
Fortschritte der Urologie und Nephrologie 1985; 23: 19-23.
- C11. Papapoulos SE
Current views on the diagnosis and treatment of hypocalcaemic states.
In: Krans HMJ ed. *Ontwikkelingen in de klinische endocrinologie*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde 1986: 115-121.
- C12. Papapoulos SE, Bosma L.
Calciumuitwisseling tussen binnen- en buitenwereld.
Nederlands Tijdschrift voor Dietisten 1986; 41: 210-211.
- C13. Bijvoet OLM, Papapoulos SE, Löwik CWGM, Harinck HIJ,
Manipulation of cell-cell interaction in bone with bisphosphonate in the interpretation of bone and calcium homeostasis in man.
In: Cohn DV et al eds. *Calcium Regulation and Bone Metabolism- Basic and Clinical Aspects* vol 9. Amsterdam, Excerpta Medica 1987: 93-104.
- C14. Valkema R, Papapoulos SE, Vismans F-JFE, Pauwels EKJ, Bijvoet OLM.
A four year continuous gain in bone mass in APD-treated osteoporosis.
In: Christiansen C et al eds. *Osteoporosis 1987*. Denmark, Osteopress ApS 1987: 836-839.
- C15. Kok DJ, Papapoulos SE, Bijvoet OLM.
Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers.
Contributions to Nephrology 1987; 58: 73-77.
- C16. Kok DJ, Papapoulos SE, Bijvoet OLM.
A physicochemical explanation for the role of citrate in recurrent stone disease.
Fortschritte der Urologie und Nephrologie 1987; 25: 284-288.
- C17. Papapoulos SE, vd Berg H, Frolich M, Valentijn RM.
Intravenous administration of 1 α -hydroxycholecalciferol in haemodialysed patients: dose-dependent increase in circulating 1,25-dihydroxycholecalciferol.
In: Norman AW et al eds. *Vitamin D; Molecular, Cellular and Clinical Endocrinology*. Berlin, Walter de Gruyter 1988; 785-786.

- C18. Papapoulos SE, Bijvoet OLM, Frolich M, vd Berg H.
Serum calcium can modulate the production of 1,25-dihydroxyvitamin D independently of PTH in man.
In: Norman AW et al eds. *Vitamin D; Molecular, Cellular and Clinical Endocrinology*. Berlin, Walter de Gruyter 1988; 997-998.
- C19. Kok DJ, Papapoulos SE, Bijvoet OLM.
The effects of low and high molecular weight substances on citrate-induced changes of growth and agglomeration of calcium oxalate crystals.
Fortschritte der Urologie und Nephrologie 1988; 26: 159-163.
- C20. Papapoulos SE.
The clinical interpretation of calciotropic hormone measurements.
In: van der Heide D, Papapoulos SE eds. *Klinische Endocrinologie in de Algemene Interne Geneeskunde Praktijk*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde 1988: 67-82.
- C21. Papapoulos SE.
Glucocorticoid effects on calcium and bone metabolism.
In: van der Heide D, Papapoulos SE eds. *Klinische Endocrinologie in de Algemene Interne Geneeskunde Praktijk*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde 1988: 147-153.
- C22. Frölich M, Papapoulos SE.
Resistance to calciotropic hormones in man.
Tijdschrift NVKC 1988; 13: 108-110.
- C23. Kok DJ, Papapoulos SE, Que I, Bijvoet OLM.
The relationship between citrate and calcium oxalate crystal agglomeration.
In: Walker VR et al eds. *Urolithiasis*. New York, Plenum Press 1989: 105-108.
- C24. Kok DJ, Papapoulos SE, Que I, Bijvoet OLM.
Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.
In Walker VR et al eds. *Urolithiasis*. New York, Plenum Press 1989: 215.
- C25. Valkema R, Verheij LR, Blokland JAK, Papapoulos SE, Bijvoet OLM, Pauwels EKJ.
Precision of DPA is limited by variations in soft tissue.
In: Schmidt HAE and Chambron J eds. *Nuclear Medicine, Quantitative Analysis in Imaging and Function*. Stuttgart, Schattauer Verlag 1990: 457-459.
- C26. Bijvoet OLM, Valkema R, Löwik CWGM, Papapoulos SE.
The use of bisphosphonates in osteoporosis.
In: DeLuca HF and Mazess R eds. *Osteoporosis, Physiological Basis, Assessment and Treatment*. New York, Elsevier 1990: 331-338.
- C27. Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE.
Effects of changes in salt and protein intake on calcium oxalate monohydrate crystallization kinetics in urines of healthy men.
In: Vahlesink W et al eds. *Urolithiasis* Amsterdam, Excerpta Medica 1990: 15- 18.
- C28. Löwik CWGM, vd Pluijm G, Bloys H, Hoekman K, Bijvoet OLM, Aarden LA, Papapoulos SE.

- IL-6 produced by PTH-stimulated osteogenic cells can be a mediator in osteoclast recruitment.
In Cohn DV et eds. *Calcium Regulation and Bone Metabolism; Basal and Clinical Aspects*. Amsterdam, Elsevier 1990; 10: 336-343.
- C29. Papapoulos SE, Kok DJ.
The role of crystal agglomeration in calcium oxalate urolithiasis.
Colloque Scientifique sur la Lithiase Renale 1990: 45-52.
- C30. Papapoulos SE, Bijvoet OLM, Valkema R, Landman JO, Papapoulou V, Pauwels EKJ, Hamdy NAT, Vermeij P.
New bisphosphonates in the treatment of osteoporosis.
In: Christiansen C and Overgaard K eds. *Osteoporosis 1990*. Copenhagen, Osteopress ApS 1990; 1294-1300.
- C31. Papapoulos SE, Papapoulou V.
Glucocorticoids and bone.
Progress in Endocrine Research and Therapy 1990; 5: 211-218.
- C32. Verheij LF, Blokland JAK, Papapoulos SE, Pauwels EKJ.
Comparison of dual photon absorptiometry images of the spine.
In: Schmidt HAE and vd Schoot JB eds. *Nuclear Medicine, The State of the Art in Europe*. Stuttgart, Schattauer Verlag 1991; 324-326.
- C33. Papapoulos SE.
Bisphosphonates: Pharmacological and pharmacodynamic properties and application to the treatment of patients with osteoporosis.
In: Douglas RG Jr ed. *Assessment and Management of risks associated with Hyperlipidemia, Osteoporosis and Hepatitis-B: Effectiveness of intervention*. Philadelphia, Hanley & Belfus Inc. 1991 : 49-57.
- C34. Papapoulos SE.
Calcium homeostasis.
In: Duursma SA et al eds. *De bijnaderklier; 25 jaar bot- en calciumresearch in Utrecht*. Utrecht, Werkgroep Botstofwisseling 1991:7-10.
- C35. Papapoulos SE.
Diagnosing osteoporosis; the clinician's approach.
In: Hamerlynck JVThH et al eds. *Osteoporose*. Amsterdam, PAOG 1992: 14-17.
- C36. Papapoulos SE.
Behandeling van osteoporose met bisfosfonaten.
In: Hamerlynck JV ThH et al eds. *Osteoporose*. Amsterdam, PAOG 1992:47-52.
- C37. Papapoulos SE.
Bisphosphonates in osteoporosis: is the optimism justified?
Norland News 1992; 3: 2-5.
- C38. Papapoulos SE
Osteomalacia.
In: *Botweefsel; Fysiologie, Pathologie en Klinische Aspecten*. Centrale Cursus Ortopaedicische Chirurgie. Boerhaave Commissie, Leiden. 1992: 141-143.
- C39. Papapoulos SE.

- Paget's disease of bone.
In: *Botweefsel; Fysiologie, Pathologie en Klinische Aspecten*. Centrale Cursus Ortopaedicische Chirurgie. Boerhaave Commissie, Leiden. 1992: 151-156.
- C40. Papapoulos SE.
Aetiology and treatment of hypercalcaemia.
Ostoun 1992; 3: 59-62.
- C41. Papapoulos SE.
Fatti e prospettive nel trattamento della osteoporosis nell' anziano con bisfosfonati.
Giornale di Gerontologia 1992; 40: 543-548.
- C42. Papapoulos SE.
Prevention of osteoporosis; state of the art.
In Springer MP ed. *Vorderingen en Praktijk*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, 1992: 169-178.
- C43. Papapoulos SE.
Bisphosphonates: pharmacology and clinical applications. In: Scellens JHM, Breimer DD, Meinders AE (eds). *Medicamenteuze Therapie; Implicaties van nieuwe inzichten voor klinisch handelen*. Leiden: Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, 1993: 65-72
- C44. Papapoulos SE.
New developments in the use of bisphosphonates for the treatment of patients with osteoporosis.
In: Duursma S, Raymakers JA eds. *Osteoporose: Wat is er nieuw?* Utrecht: Stichting Postuniversitair Onderwijs, 1993: 39-43.
- C45. Papapoulos SE, Hamdy N, Valkema R, Pauwels E, Kroon H, Papapoulou V.
The effects of long-term uninterrupted treatment with bisphosphonates on the growing skeleton.
In: Christiansen C, Riis BJ eds. *Osteoporosis 1993*. Aalborg: Handelstrykkeriet Aalborg ApS, 1993: 210-211.
- C46. Papapoulos SE, Landman JO, Papapoulou V.
Antiresorptive treatments in patients with established osteoporosis.
In: Mornex R, Jaffiol C, Leclere J eds. *Progress in Endocrinology*, Carnforth: The Parthenon Publishing Group, 1993: 423-426.
- C47. Schweitzer DH, Papapoulos SE.
De ziekte van Paget.
Geriatric Informatarium 1994; C1510: 1-8.
- C48. Papapoulos SE.
Calcitonin and bisphosphonate therapies in elderly patients.
In: Duursma SA, Jansen PAF, Raymakers JA eds. *Osteoporose en heupfracturen bij ouderen*. Utrecht: Afdeling Geriatrie AZU, 1994: 81-87.
- C49. van der Pluijm G, Papapoulos S.
Tumor-geïnduceerde botafbraak bij patienten met borstkanker.
Cytokinen 1994; 2: 9-11.

- C50. Papapoulos SE.
Osteoporosis in men and children.
In: *Osteoporose: Huisarts Centraal*, Osteoporose Stichting, 1994: 31-34.
- C51. Kok DJ, Papapoulos SE.
Relationships between inhibitor structure and its effects on calcium oxalate monohydrate crystallization kinetics.
In: Ryall R, Biaz R, Marshall VR, Rofe AM, Smith LH, Walker VR eds. *Urolithiasis 2*. New York: Plenum Press 1994: 230.
- C52. Papapoulos SE.
Growing bone normal following bisphosphonate treatment.
Rheumatology News 1995; 23: 1-5.
- C53. Brumsen C, Papapoulos SE.
Osteoporose; niet alleen een vrouwenkwaal.
De Papieren Visite 1995; 14: 7-8.
- C54. Papapoulos SE.
Parathyroid hormone-related proteins.
In: Weber RFA ed. *Endocrinologie 1995*, Novo Nordisk 1995: 19=20.
- C55. Papapoulos S.
Bisphosphonates in the treatment of osteoporosis.
Ostoun 1995; 6: 305-306.
- C56. Papapoulos SE.
Glucocorticoid-induced osteoporosis.
In: Papapoulos SE, Lips P, Pols H, Johnston C, Delmas PD eds. *Osteoporosis 96*, Amsterdam: Elsevier Science 1996: 359-367.
- C57. Papapoulos SE.
Osteoporosis: problem only of the individual? Conclusions from epidemiological studies.
Ostoun 1996; 7: 216-218.
- C58. Papapoulos SE.
Bisphosphonates: pharmacology and rationale for their use in the prevention and treatment of glucocorticoid-induced osteoporosis.
In : Hamdy NAT et al eds. *Glucocorticoids and bone: the clinical problem*. Leiden: Boerhaave Committee for Postgraduate Education 1997: pp 83-92.
- C59. Papapoulos SE.
Bisphosphonates: structure-activity relations from a clinical perspective.
Medicina 1997; 57 (Suppl I): 61-64.
- C60. van Holtten-Verzantvoort ATM, Papapoulos SE.
Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
Medicina 1997; 57 (Suppl I): 109-113.
- C61. Papapoulos SE.
Pathophysiology and management of metastatic bone disease.
Ostoun 1997; 8: 296-297.

- C62. Papapoulos SE.
Treatment of osteoporosis.
Ostoun 1997; 8: 322-323.
- C63. Papapoulos SE.
Bisphosphonates in osteoporosis; pharmacological and clinical aspects.
In: Lyritis G ed *Advances in Osteoporosis*, vol 1; Athens: Hylonome Editions, 1998: pp 107-112.
- C64. Papapoulos SE.
Bisphosphonate pharmacology; basic and clinical aspects.
International Bone Forum 1998 (7): pp 74-79.
- C65. Papapoulos SE.
The Clinical Management of Osteoporosis.
In: *Proceedings of the 3rd International Symposium on Women's Health and Menopause*. Giovanni Lorenzini Medical Foundation, Houston, 1999.
- C66. van Beek ER, Lowik CWGM, Papapoulos SE.
Nieuwe inzichten in het werkingsmechanisme van bisfosfonaten.
Nederlands Tijdschrift voor Osteoporose en Andere Botziekten 2000; 4: 51-54.
- C67. Papapoulos SE
The consequences and prevention of hip fractures.
OsteoUpdate 2000; 1.3: 1.
- C68. Papapoulos SE
Selective Estrogen Receptor Modulators (SERMs) in the prevention and treatment of osteoporosis.
http://WomensHealth.medscape.com/medscape/cno/2000/WCO/public/Conference.Cfm?conference_id=58.
- C69. Papapoulos SE.
Estrogens and Selective Estrogen Receptor Modulators (SERMs) ; what's new ?
A clinical perspective.
http://www.medscape.com/Medscape/CNO/2000/ASBMR/public/Conference.cfm?conference_id=73.
- C70. Papapoulos SE.
Pharmacologic management of osteoporosis ; methodologic issues and results of intervention studies.
<http://www.medscape.com/Medscape/WomensHealth/TreatmentUpdate/2000/tu04/public/toc-tu04.html>.
- C71. Papapoulos SE.
Paget's disease of bone.
Medicine 2001; 29:12: 71-73.
- C72. Papapoulos SE.
Metastatic bone disease and Paget's disease of bone.
<http://www.medscape.com/Medscape/CNO/2001/IBMSCME>
- C73. Papapoulos SE.
Yearly bisphosphonate infusions in the management of osteoporosis?

- IBMS BoneKEy 2002 Apr 8 10.1138/ibmske; 2002035.***
- C74. Papapoulos SE.
Anything new in the use of bisphosphonates in the management of osteoporosis?
IBMS BoneKEy 2002/ibmske; 2002065v1
- C75. Papapoulos SE.
New ways of bisphosphonate administration in osteoporosis.
www.medscape.com/434335/2002
- C76. van der Pluijm G, Papapoulos S, Lowik C.
Mechanismen van skeletmetastasering bij borstkanker. Nieuwe inzichten en therapeutische mogelijkheden.
***Nederlands Tijdschrift voor Osteoporose en andere Botziekten* 2002; 6: 51-58.**
- C77. Papapoulos SE.
Long-term therapy of osteoporosis with bisphosphonates: evidence and implications for daily practice.
***BoneKEy-Osteovision* 2005; 2:13-19.**
- C78. Papapoulos SE
Evolution in the diagnosis and management of osteoporosis: Practical implications.
***Endocrinologie voor de Huisarts* (ISBN: 90-6767-580-6) 2005; pp 39-43.**
- C79. van Bezooijen RL, Papapoulos SE, Hamdy NA, ten Dijke P, Löwik CW.
Control of Bone Formation by Osteocytes? Lessons from the Rare Skeletal Disorders Sclerosteosis and van Buchem Disease.
***BoneKEy-Osteovision* 2005; 2: 33-38.**
- C80. Papapoulos SE.
Osteoporosis Assessment and Treatment
In: Cornish J, Kronenberg HM, Rogers MJ, Papapoulos SE, Mundy GR.
Meeting Report from the 2nd Joint Meeting of the ECTS and the IBMS.
***BoneKEy-Osteovision* 2006; 3:18-28**

D. PUBLISHED ABSTRACTS (number only): 390.

**E. SELECTED INVITED LECTURES.
(only recent; since January 2000).**

January 24-27, 2000; Lyon, France.

IOF Advanced Training Course in Osteoporosis and Bone Diseases.

Titles: Glucocorticoid-induced osteoporosis; Tumoral bone disease and hypercalcemia of malignancy; Design of clinical trials in osteoporosis.

March 8, 2000; Cairo, Egypt.

1st Annual Congress of the Egyptian Society for Osteoporosis.

Title: Evidence-Based Medicine in osteoporosis

April 5, 2000; Davos, Switzerland.

5th Workshop on Bisphosphonates

Title: Use of bisphosphonates in Paget's and other diseases.

April 12; Bath, UK.

7th Bath Conference on Osteoporosis.

Title: Bisphosphonates for the prevention and treatment of osteoporosis

May 19-21,2000; Delphi, Greece

2nd International Workshop on Musculoskeletal Interactions

Titles: Evidence-based medicine; principles and application in osteoporosis.

June 5, 2000; Antalya; Turkey

12th European Congress of Physical Medicine and Rehabilitation

Title: Evidence-Based Medicine; background and considerations for intervention studies in osteoporosis.

June 18, 2000; Chicago, USA.

World Congress on Osteoporosis

Title: Bisphosphonates in the treatment of postmenopausal osteoporosis.

June 24, 2000; Nice, France.

The EULAR Annual Congress

Title: How to prevent fractures.

June 30, 2000; Tel Aviv, Israel

The Sarnat Lecture in Bone Biology ; Dental School of Medicine ; University of Tel Aviv.

Title: Basic and Clinical Pharmacology of the Bisphosphonates.

September 10, 2000; Turku, Finland

28th Scandinavian Congress of Rheumatology

Title: Treatment of osteoporosis.

September 23, 2000; Toronto, Canada.

ASBMR; Satellite Symposium (CME)

Titles: Evidence-Based Medicine evaluation of the antifracture efficacy of bisphosphonates;
Are all bisphosphonates the same? from molecule to clinical practice.

October 6, 2000; Beirut, Lebanon.
1st Pan Arab Congress on Osteoporosis.
Title: Bisphosphonates in the treatment of postmenopausal osteoporosis.

October 30, 2000; Sydney, Australia
11th International Congress of Endocrinology
Title: The pathogenesis of Paget's disease of bone.

February 22-24, 2001; Siena, Italy.
First International Conference on Osteoporosis in Men.
Title: Bisphosphonates in men.

March 3, 2001; Mont-Pelerin, Switzerland.
15^{eme} symposium sur l'osteoporose.
Title: Osteoporosis in general practice.

June 6, 2001; Madrid, Spain.
IBMS-ECTS Congress; Satellite Symposium (CME)
Title: The role of EBM in the management of osteoporosis

June 12, 2001; Torino, Italy.
5th European Congress of Endocrinology (EFES).
Meet the expert: hypercalcaemia.

January 22-24, 2002; Lyon, France
IOF Advanced Training Course in Osteoporosis and Bone Diseases.
Titles: Glucocorticoid-induced osteoporosis; Design of intervention studies in osteoporosis;
Tumoral bone disease.

March 3, 2002; Hong Kong, China
3rd Osteoporosis Symposium
Titles: Clinical utility of bone mass measurements; antifracture efficacy of therapeutic agents: a critical review of the evidence.

March 22, 2002; Davos, Switzerland
6th International Workshop on Bisphosphonates; From the laboratory to the patient
Title: Is today's mode of administration of bisphosphonates optimal?

April 11, 2002; Padova, Italy.
Postgraduate Course on Metabolic Bone Diseases; Mediterranean Society for Osteoporosis and other Skeletal Diseases.
Title: Osteoporosis: an underdiagnosed disease

12.05.02; Lisbon, Portugal.
World Congress on Osteoporosis.
Titles: Practical management of osteoporosis; the European perspective (meet the Professor);

June 12, 2002; Berlin, Germany.
10th International Congress on the Menopause.
Title: Bisphosphonates in the management of established osteoporosis.

June 13, 2002; Torino, Italy.
12th Postgraduate Course in Metabolic Bone Diseases.
Title: Evidence-Based Medicine approaches in the treatment of Osteoporosis

June 25, 2002; Cardiff, UK
Bone and Tooth Society of Great Britain
Title: Future therapies for osteoporosis.

August 27, 2002; Tokyo, Japan.
4th Bisphosphonate Forum.
Title: Glucocorticoid-induced osteoporosis: pathophysiology and therapeutic considerations.

September 23, 2002; San Antonio TX, USA.
ASBMR.; State of the Art Lecture
Title: Developments in the clinical use of bisphosphonates: facts and questions.

October 27, 2002; New Orleans Louisiana, USA.
American College of Rheumatologists 66th Annual Meeting
Title: Bisphosphonates in children; general considerations.

December 12, 2002; Cincinnati, Ohio, USA.
Grand Round Internal Medicine, University of Cincinnati.
Title: Bisphosphonates and the growing skeleton.

January 24-26, 2003; Lyon, France.
IOF Advanced Training Course in Osteoporosis and Bone Diseases.
Titles: Glucocorticoid-induced osteoporosis; Design of intervention studies in osteoporosis; Tumoral bone disease.

April 4, 2003; Genova, Italy.
2nd International Conference on Male Osteoporosis.
Title: Bisphosphonates in the management of male osteoporosis.

April 17, 2003; Athens, Greece
Annual Congress of the Hellenic Society for the Study of Bone Metabolism.
Title: Pharmacotherapy of osteoporosis; the future.

May 21, 2003; Balatonfüred, Hungary.
13th Congress of the Hungarian Society for Osteoporosis and Osteoarthritis.
Title: Glucocorticoid-induced osteoporosis

June 7, 2003; Osaka, Japan.
IBMS-JSBMM meeting

Title : Angiogenesis and bone metastases.

June 21, 2003; Lisbon, Portugal
EULAR 2003

Title: Critical review of treatments for osteoporosis

July 14, 2003; Manchester, Vermont, USA
17th Annual Symposium on Estrogens.

Title: How long should we treat?

October 3, 2003; Beirut, Lebanon

2nd International Conference of the Mediterranean Society for Osteoporosis.

Title: Bisphosphonates in the management of postmenopausal osteoporosis.

October 9, 2003; Krakow, Poland

12th Congress of Polish Society of Osteoarthrology and the Polish Foundation of Osteoporosis.

Title: Pharmacological management of osteoporosis: state of the art.

February 03-05, 2004; Lyon, France.

IOF Advanced Training Course in Osteoporosis and Bone Diseases.

Titles: Glucocorticoid-induced osteoporosis; Design of interventions studies in osteoporosis; Tumoral bone disease and hypercalcemia of malignancy.

March 12, 2004; Ostuni, Italy.

Postgraduate Course in Metabolic Bone diseases; Mediterranean Society for Osteoporosis and Bone Diseases.

Title: Paget's disease of bone.

March 24, 2004; Davos, Switzerland

7th International Workshop on Bisphosphonates; From the laboratory to the patient .

Title: The pharmacology of bisphosphonates .

April 2, 2004 ; Lisbon, Portugal

12th Portuguese Congress of Rheumatology

Title: Bone quality; What clinicians need to know.

April 30, 2004; Limnos, Greece.

12th Congress EMMO

Title: Too much bone

May (13-17) 2004; Rio de Janeiro, Brasil

IOF Congress on Osteoporosis

Titles: Osteoporosis treatment: what does the future hold? Meet the Professor
session: How long should we treat for?

May 22, 2004; Ayrshire, Scotland

Clinical Update on the Management and treatment of Osteoporosis.

Title: Update on the medical management of osteoporosis.

October 3, 2004; Seattle, USA

26th Annual Meeting of the ASBMR; CME Symposium.

Title: Long-term outcomes with bisphosphonates in osteoporosis.

October 15, 2004; Carzago, Italy

Skeletal Endocrinology 2004; Bone Anabolic Hormones.

Title: Bone Morphogenetic proteins and their antagonists: Basic concepts and clinical applications

October 29, 2004; Venice, Italy

New perspectives: Bone Involvement in Arthritis

Title: Bisphosphonates and arthritis.

November 15, 2004; Pisa, Italy.

5th International Menopause Society Workshop

Titles: Bisphosphonates in the prevention and treatment of osteoporosis; Mechanism of antifracture efficacy of bisphosphonates.

January 22, 2005; Florence, Italy.

1st International Meeting on Pharmacogenetics of Osteoarticular Disorders.

Title: Extraskelatal effects of osteoporosis treatments.

February 1-3, 2005; Lyon, France.

IOF Advanced Training Course in Osteoporosis and Bone Diseases.

Titles: Bisphosphonates:preclinical aspects and safety; How to design clinical trials in osteoporosis in 2005; Tumoral bone disease and hypercalcemia of malignancy.

February 16, 2005; New Orleans, USA.

11th Annual Meeting of the International Society for Clinical Densitometry.

Title: New concepts concerning bone strength.

March 4, 2005; Athens, Greece.

3rd National Conference of the Climacteric and the Menopause.

Title: Treatment of postmenopausal osteoporosis: what the future holds?

March 24, 2005; Davos, Switzerland.

Cancer-Induced Bone Disease

Title: Lessons from postmenopausal osteoporosis for cancer clinicians.

April 7, 2005; Washington DC, USA.

6th International Symposium on Osteoporosis (NOF, USA).

Title: What is treatment failure and what should be done about it?

May 20, 2005; Pescara, Italy

Congress of the Italian Society for Rheumatology.

Title: Treatment of osteoporosis in the future.

June 27, 2005; Geneva, Switzerland
ECTS-IBMS Joined Meeting.
Meet the Professor:

August 28, 2005; Taipei, Taiwan.
Annual Meeting of the Taiwanese Society for Osteoporosis
Title: Osteoporosis: Development in diagnosis and treatment

September 2, 2005; Naantali, Finland
5th Baltic Bone and Cartilage Congress
Title: Paget's disease: Characteristics and treatment principles

September 4, 2005; Gottenborg, Sweden
European Congress of Endocrinology
Title: Bisphosphonates: Mechanism of action.

September 8, 2005; Tunis, Tunisia.
3rd Pan Arab Congress on Osteoporosis.
Title: How long should we treat for?

September 17, 2005; Rhodes, Greece
1st International Meeting on Bone Strength and Quality Parameters
Title: Biomarkers

September 23, 2005; Nashville, USA.
27th Annual Meeting of the ASBMR; Symposium: The periosteum, a target for all seasons
Title: The periosteum as target of treatments

October 2, 2005; Napoli, Italy
Mediterranean Congress of Osteoporosis and Bone Diseases
Title: Bisphosphonates: Long-term efficacy and safety

October 7, 2005; Krakow, Poland.
1st Central European Congress of Osteoporosis and Osteoarthritis
Title: The evolution of bisphosphonate treatment of osteoporosis

October 14, 2005, Kaunas, Lithuania
2nd Baltic Conference of Osteoporosis
Title: Osteoporosis: How long should we treat for?

November 10, 2005, Wentbridge, UK
21st Symposium on Practical Medicine for Old Age
Title: Advances in the management of osteoporosis

November 18, 2005; Coimbra, Portugal
17th Course in Rheumatology

Title: Evidence-based treatment of osteoporosis; state-of-the art

November 26, 2005; Athens, Greece

Osteoporosis Update

Title: Control of bone formation by osteocytes and its implications in the treatment of osteoporosis.

January 14, 2006; Fort Lauderdale, USA

Paget's Disease of Bone/Fibrous Dysplasia: Advances and Challenges

Title: Resistance to bisphosphonates in Paget's disease.

January 31-February 2, 2006; Lyon, France.

15th IOF Advanced Training Course in Osteoporosis

Titles: Bisphosphonates preclinical pharmacology and safety; Tumoral bone disease; Planning clinical trials in 2006.

March 17, 2006; Vienna, Austria.

6th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.

Title: Update on the management of secondary osteoporosis; clinical and economic aspects.

March 22, 2006; Davos Switzerland.

8th Workshop on Bisphosphonates.

Title: Bisphosphonates: Pharmacology, pharmacokinetics and adverse effects.

March 31, 2006; Athens, Greece

Greek Congress of Endocrinology

Title: Bisphosphonates: beyond weekly administration

April 7, 2006; Thessaloniki, Greece

Annual Congress EEMMO

Title: Treatment failure in osteoporosis

April 29, 2006; Azores, Portugal.

Portugese Congress of Rheumatology

Title: Future treatments of osteoporosis

May 10, 2006; Prague, Czech Republic

ECTS meeting

Title: Meeting overview (for allied health professionals)

May 30, 2006; Boston, USA

Boston IV Meeting on Bone and Cartilage Diseases

Title: Synergy and Interference in combining antiresorptive and anabolic therapy.

June 6, 2006; Toronto, Canada

IOF Congress on Osteoporosis

Title: Rationale for choosing antiresorptive or anabolic treatments

September 9, 2006; Corfu, Greece.

2nd International Scientific Meeting Bone Quality Parameters and Bone Strength.

Titles: Interpretation of BMD measurements; Oversuppression of bone turnover.

September 16, 2006; Philadelphia, USA.

28th Annual ASBMR Meeting

Title: Osteoporosis: New targets of Therapy

October 13, 2006; Tokyo, Japan

Joined meeting of the JOS and the ASBMR

Title: Targeting the bone remodeling imbalance of osteoporosis with intravenous bisphosphonates or inhibitors of sclerostin

October 21, 2006; Venice; Italy

Title: Is there a role for bisphosphonates in inflammatory arthritis?

November 3, 2006; The Hague, The Netherlands

European Congress of Oncology

Title: Pathophysiology of bone metastases

January 30, February 1, 2007; Lyon, France

16th IOF Advanced Training Course in Osteoporosis

Titles: Bisphosphonates preclinical pharmacology and safety; Tumoral bone disease; Planning clinical trials in 2007.

April 28, 2007; Kaoshiung, Taiwan

52nd Congress Taiwan Orthopaedic Association

Title: Bisphosphonates in the management of osteoporosis; efficacy and long-term safety.

May 1, 2007; Budapest, Hungary

European Congress of Endocrinology

Title: Sclerostin: an osteocyte-produced regulator of bone formation

May 5, 2007; Copenhagen, Denmark

ECTS Training Course: Bone Quality, from bench to bedside

Title: Oversuppression of bone remodeling

May 19, 2007; New York, USA

NY Academy of Sciences: Bisphosphonates & Osteonecrosis of the Jaw

Title: Use of bisphosphonates in osteoporosis

May 26, 2007; Paphos, Cyprus

15th Annual Meeting of the Hellenic Society for the Study of Bone Metabolism

Title: Follow-up of osteoporosis treatments

June 28, 2007; Montreal, Canada
CME Symposium at the 17th IBMS Meeting
Title: Cathepsin K inhibition: A novel mechanism of action.

July 12, 2007; Oxford, UK.
Advances in the Molecular Pharmacology and Therapeutics of Bone Disease & International Symposium on Paget's Disease.
Title: Bisphosphonates and oversuppression of bone turnover: weighing the evidence.

September 16, 2007; Honolulu, USA.
29th ASBMR Meeting; Debate.
Title: Excessive suppression of bone turnover with antiresorptive therapies: fact or fiction?

September 29, 2007; Samos, Greece.
3rd International Meeting " Bone Quality Parameters & Bone Strength"
Title: Malignant diseases and the skeleton.

October 11, 2007. Krakow, Poland.
2nd Central European Congress on Osteoporosis and Osteoarthritis.
Title: Rationale for using anabolic and antiresorptive treatments in osteoporosis.

November 15, 2007; Florence, Italy
7th National Congress of the Italian Society for Osteoporosis, Mineral Metabolism and Diseases of the Skeleton.
Title: Targeting rank ligand for treatment of bone loss disorders.

December 6, 2007; Washington DC, USA.
Targeting Bone Remodeling for the Treatment of Osteoporosis; ASBMR Meeting.
Organizing Committee, Speaker.
Title: Bisphosphonates: Clinical Aspects

January 29-31, 2008; Lyon, France.
17th IOF Advanced Training Course in Osteoporosis
Titles: Bisphosphonates preclinical pharmacology and safety; Tumoral bone disease; Planning clinical trials in 2008.

March 2,3, 2008; Dubai, UAE.
4th Pan Arab Osteoporosis Conference.
Title: Excessive suppression of bone turnover by bisphosphonates: weighing the evidence; Identification of molecular defects of rare bone diseases provides targets for development of novel osteoporosis therapies.

March 13, 2008; Davos, Switzerland.
IBMS Davos Workshops: Bone Biology & Therapeutics (member Steering Committee; speaker)
Title: Bisphosphonates: Current clinical issues.

April 9-12, 2008. Istanbul, Turkey.
ECCEO 08 Congress
Meet the Professor: Management of glucocorticoid induced osteoporosis.

April 24, 2008; Berne Switzerland.
Meeting of the Swiss Association against Osteoporosis
Title: Bisphosphonates: Which and for how long?

May 26, 2008; Barcelona, Spain.
ECTS; 35th European Symposium on Calcified Tissues
Title: Optimization of osteoporosis treatment.

June 6, 2008; Kos, Greece
16th Annual Meeting of the Hellenic Society for the Study of Bone Metabolism.
Title: Identification of individuals at risk for osteoporotic fractures.

September 13, 2008; Montreal, Canada.
ASBMR, CME Program: Expanding the spectrum of osteoporosis treatment.
Title: Patient selection for treatment and bisphosphonate options.

September 14, 2008; Montreal, Canada.
ASBMR, CME Program: The treatment of osteoporosis: where are we now and do the emerging therapeutic agents offer a brighter future?
Title: Future strategies for the treatment of osteoporosis

September 26, 2008; Delphi, Greece.
11th International Workshop on Multiple Endocrine Neoplasia.
Title: Medical treatment of hypercalcaemia.

October 1, 2008; Santa Margherita, Italy.
4th International Conference on Bone Involvement in Arthritis.
Title: Bisphosphonate pharmacology; An overview.

October 17, 2008; Antalya, Turkey.
3rd National Osteoporosis Congress.
Title: Excessive suppression of bone remodeling by bisphosphonates: weighing the evidence.

November 6, 2008; Oviedo, Spain.
13th Congress of the SEIOMM
Title: New therapeutic targets for osteoporosis: inhibition of cathepsin K.

November 10, 2008; Rio de Janeiro, Brazil
International Congress of Endocrinology 2008
Title: Osteoporosis-treatment monitoring and how long for?

November 21, 2008; Perugia, Italy.

8th National Congress SIOMMMS

Title: Treatment of osteoporosis: State of the Art.

February 3-5, 2009; Lyon, France.

18th IOF Advanced Training Course in Osteoporosis

Titles: Bisphosphonates preclinical pharmacology and safety; Tumoral bone disease; Planning clinical trials in 2009.

March 19, 2009; Athens, Greece

ECCEO9-IOF

Title: How to present scientific data in a first-line meeting: strengths and weaknesses.

March 21, 2009; Athens, Greece.

ECCEO9-IOF

Debate: Long-term use of bisphosphonates in osteoporosis is bad.

March 27, 2009; Prague, Czech Republic.

41st International Symposium on Endocrinology & Metabolism

Title: Treatment of secondary osteoporosis by bisphosphonates: a pediatric perspective.

April 22, 2009; Thessaloniki, Greece

28th Annual Congress of Orthopaedics & Traumatology Association of Northern Greece.

Title: The future of Osteoporosis Treatment

April 26, 2009; Istanbul, Turkey.

11th European Congress of Endocrinology.

Title: Current and novel treatment targets of bone diseases

May 16, 2009; Crete, Greece.

17th Annual Meeting of the Hellenic Society for the Study of Bone Metabolism

Title: Subtrochanteric/diaphyseal femur fractures and bisphosphonates.

July 8, 2009; Oxford UK

NARPD Conference 2009

Title: The development of bisphosphonates in Leiden.

September 12, 2009; Denver Co, USA.

ASBMR Annual Meeting;

Meet-the Professor: Do we know everything about bisphosphonates in osteoporosis?

October 24, 2009; Krakow, Poland.

3rd Central European Congress on Osteoporosis and Osteoarthritis.

Title: Treatment of osteoporosis beyond 5 years.

November 19, 2009; Torino, Italy.

9th Annual Congress SIOMMMS

Title: Bisphosphonates and the femur; facts and questions

January 16, 2010; Brussels, Belgium..

Belgian Bone Club

Title: The clinical significance of inhibiting the RANK/RANKL signaling pathway.

February 2-4, 2010, Lyon, France.

19th IOF Advanced Training Course in Osteoporosis

Course leader

Titles: Bisphosphonates preclinical pharmacology and safety; Perspectives in osteoporosis treatment; Planning clinical trials in 2010.

February 29, 2010, Athens, Greece.

Hellenic Society for Endocrinology

Title: Targeting Cathepsin-K and Sclerostin for the treatment of osteoporosis

April 17, 2010; Mandelieu, France.

Vienna Academy of Postgraduate Education & Research

Title; Targeting sclerostin as novel treatment for osteoporosis

May 5-8, 2010; Florence, Italy.

IOF WCO – ECCEO 10

Title: Emerging treatments for osteoporosis

Meet the Professor: Bisphosphonates and chronic renal failure

May 15, 2010; Athens, Greece

18th Annual Meeting of EEMMO

Title: Novel approaches to anabolic treatment of osteoporosis

September 11, 2010; Genova, Italy.

Bone Involvement in Arthritis

Title: RANKL inhibition in osteoporosis and rheumatoid arthritis

September 23, 2010; Luxemburg

14th Belgian Congress on Rheumatology

Title: Denosumab in postmenopausal osteoporosis.

September 25, 2010; Sopron, Hungary

8th Central European Congress of Rheumatology

Title: RANKL inhibition in the management of postmenopausal osteoporosis; clinical evidence.

September 25, 2010; Genova, Italy.

International Congress on Osteoporosis in Men

Title: From high bone mass diseases to the future of osteoporosis treatment; the sclerostin paradigm.

November 27, 2010; Vienna, Austria.
Autumn meeting of the Austrian Society for Bone and Mineral Research.
Title: Targeting sclerostin; a novel approach to anabolic treatment of osteoporosis.

February 1-3, 2011; Geneva, Switzerland
20th IOF Advanced Training Course in Osteoporosis
Course leader
Titles: Bisphosphonates preclinical pharmacology and safety; Perspectives in osteoporosis treatment; Planning clinical trials in 2011.

February 10, 2011; Leiden, The Netherlands
Boerhaave Cursus Endocrinologie
Title: Osteoporosis

March 26, 2011; Valencia, Spain.
ESCEO-IOF Congress
Title: Future perspectives in the treatment of osteoporosis.

May 12, 2011; Athens, Greece.
ECTS/IBMS Congress
Title: Antiresorptive treatments: bisphosphonates

June 11, 2011; Rome, Italy.
13th World Congress on Menopause
Title: Treatments of osteoporosis beyond bisphosphonates

July 1, 2011; Chalkidiki, Greece
2nd Trilateral Congress on Osteoporosis and Osteoarthritis.
Title: Atypical fractures of the femur and bisphosphonate use.

September 30, 2011; Krakow, Poland
4th Central European Congress on Osteoporosis and Osteoarthritis
Title: Long-term efficacy and safety of denosumab in postmenopausal osteoporosis.

October 8, 2011; Ioannina, Greece
19th Congress EEMMO
Title: Sequential therapeutic regimens for osteoporosis; possibilities and future perspectives.

October 14, 2011; St Margherita, Italy
Osteorheumatology 2011
Title: Combination and sequential treatments in the management of osteoporosis

October 22, 2011; Dubai, UAE
IOF Regionals; 1st Middle East & Africa Osteoporosis Meeting
Title: Monitoring patients with osteoporosis

November 4, 2011; A Coruna, Spain

16th Congress SEIOMM

Title: Treatment of patients with fractures

November 18, 2011; Rome Italy

11th National Congress of SIOMMMS

Title: New therapeutic frontiers for osteoporosis

December 3, 2011; Bratislava; Slovakia

5th Central European Osteoporosis Summit

Title: Novel approaches to treatment of osteoporosis

January 20, 2012; Barcelona, Spain

World Congress on debates & Consensus in Bone, Muscle & Joint Diseases

Title: Inhibition of Sclerostin in the treatment of osteoporosis+ will it solve the problem of anabolic therapy?

January 30-February 2, 2012; Geneva, Switzerland

20th IOF Advanced Training Course in Osteoporosis

Course leader

Titles: Bisphosphonates preclinical pharmacology and safety; Perspectives in osteoporosis treatment; Planning clinical trials in 2012.

March 3, 2012; Rome, Italy

Controversies in Osteoporosis

Title: Duration of treatments for osteoporosis.

March 11, 2012; Taipei, Taiwan

33rd Annual Meeting of the Endocrine Society and the Diabetic Association of the Republic of China.

Title: Novel approaches to the treatment of postmenopausal osteoporosis.

March 22, 2012; Bordeaux, France

IOF-ECCEO 12/IOF-ECTS-FROMO Symposium

Title: Treatment of GIOP with bisphosphonates and other agents

March 23, 2012; Bordeaux, France

IOF-ECCEO 12/ Plenary lecture

Title: Building new bone; is this possible?

May 7, 2012; Florence, Italy

ICE/ESE 2012

Title: Controversial issues with bisphosphonates

July 2-3, 2012; Manchester, UK

Osteoporosis and Bone Conference 2012

Titles: Treatment of Paget's disease of bone; Osteoporosis treatment conundrums.

September 21, 2012; Brescia, Italy

5th Meeting Skeletal Endocrinology

Title: Inhibition of sclerostin and myostatin in the treatment of osteoporosis

September 28, 2012; Dead Sea, Jordan

2nd IOF Middle East and Africa Osteoporosis Meeting

Title: Pathophysiology of Osteoporosis

October 5, 2012; Rome, Italy

8th National Congress GISMO

Title: RANKL inhibition: from bench to management of osteoporosis.

October 25, 2012; Sinaia, Romania

National Congress of Rehabilitation

Title: Is anabolic treatment of osteoporosis possible?

November 17, 2012; Bologna, Italy

12th National Congress SIOMMMS

Title: Combinations and sequential treatments of osteoporosis.

January 30-February 1, 2013; Geneva, Switzerland

21th IOF Advanced Training Course in Osteoporosis

Course leader

Titles: Perspectives in osteoporosis treatment; Planning clinical trials in 2013; Bone quiz

March 18, 2013; Harrogate, UK

Annual Meeting British Endocrine Society

Title: Inhibition of sclerostin in the treatment of osteoporosis

April 19, 2013; Rome, Italy

ESCEO13-IOF Congress; Meet the Professor session

Title: Monitoring treatment of osteoporosis

April 27, 2013; Rhodos, Greece

5th National Congress EPEMY

Title: Personalizing treatment of osteoporosis

May 25, 2013; Hong Kong

14th Regional Osteoporosis Conference

Title: Selection of osteoporosis treatment to prevent fractures; challenges and latest developments.

August 29-30, 2013; Buenos Aires Argentina

30th Annual Congress Argentinian Society Osteology and Mineral Metabolism

Titles: Bisphosphonates: 40 years of clinical use; Sclerostin: from human genetics to treatment of osteoporosis.

September 20, 2013; Krakow, Poland

5th Central European Congress on Osteoporosis and Osteoarthritis
Title: Novel therapies for postmenopausal osteoporosis.

October 6, 2013; Baltimore, USA
ASBMR symposium on Sclerostin
Title: Lessons from rare bone diseases

October 15, 2013; Genova, Italy
OsteoRheumatology 2013
Title: Biologic treatments for osteoporosis.

October 25-26, 2013; Dubai, UAE
1st MEA Bone Academy.
Titles: Relationship between bone turnover and fracture risk; Issues with long-term of osteoporosis (incl AFF); Clinical efficacy and safety of OP drugs: where are the differences?

October 29, 2013; Lausanne, Switzerland
Department of Medicine CHUV
Title: From rare genetic bone diseases to treatment of osteoporosis: the sclerostin paradigm.

November 9, 2013; Volos, Greece
21st National Congress EEMMO
Title: Treatment of osteoporosis beyond bisphosphonates

February 22, 2014; Brussels, Belgium
Werkgroep Osteoporose KBV van Reumatologie
Title: New Prospects in Fracture Prevention: Odanacatib and Antisclerostin Antibodies.

March 8, 2014; Barcelona, Spain.
Bone Academy 2014; Bone dynamics
Title: Atypical Femoral Fractures; Facts, Uncertainties and Questions

March 19, 2014; Punta del Este, Uruguay
PANLAR 2014
Title: Novel approaches to the treatment of osteoporosis.

April 2, 2014; Sevilla, Spain
WCO-IOF-ESCEO 2014
Title: Best clinical papers in 2014

April 5, 2014; Sevilla, Spain
WCO-IOF-ESCEO 2014
Title: how long can bone turnover be suppressed?

June 17, 2014; Trondheim, Norway

Norwegian University of Science & Technology
Title: Treatments of osteoporosis: are they effective?

October 2, 2014; Bucharest, Romania
Annual Meeting Romanian Society of Rheumatology
Title: Biologics in the treatment of osteoporosis

October 10, 2014; Kuala Lumpur, Malaysia
9th Annual Meeting Malaysian Osteoporosis Society
Title: How long can bone turnover be suppressed?

October 11, 2014; Kuala Lumpur, Malaysia
9th Annual Meeting Malaysian Osteoporosis Society
Title: Treatments of Osteoporosis; Does benefit outweigh the risk? Antiresorptives

October 23, 2014; Tokyo, Japan
16th Annual Meeting Japan Osteoporosis Society
Title: Novel Approaches to Treatment of Osteoporosis

December 12, 2014; Florence, Italy.
9th Annual OrtoMed Congress
Title: Long-term efficacy and safety of denosumab in the treatment of postmenopausal osteoporosis.

February 27-28, 2015; Berlin, Germany.
8th Bone Academy Meeting
Co-chair, speaker
Title: Sclerostin, lessons from human genetics

March 28, 2015; Milano, Italy
WCO-IOF-ESCEO
Title: Bone anabolic therapies for osteoporosis

April 25, 2015; Rotterdam, Netherlands
ECTS-IBMS Congress
Steven Boonen Lecture
Title: From rare bone diseases to treatments of osteoporosis; the sclerostin paradigm

May 10, 2015; Rome, Italy
EULAR 2015
Title: Modern treatment of osteoporosis, the first 5 years of treatment

June 25, 2015; Bergamo, Italy
Osteorheumatology 2015
Title: Biologic therapies in osteoporosis

September 3, 2015; Edinburgh, UK
Bone Research Society

Title: Inhibition of sclerostin in the management of postmenopausal osteoporosis

September 17, 2015; Brescia, Italy

2nd Translational European Society of Endocrinology Bone Course

Title: Wnt, Bone Metabolism and Osteoporosis Treatment

September 23, 2015; Genk, Belgium

19th Belgian Congress on Rheumatology

Vesalius Lecture

Title: From antiresorptive to osteoanabolic therapy to prevent fractures

October 17, 2015; Dubai, UAE

3rd MEA Bone Academy

Titles: Fracture risk and prevention in men and women with sex-hormone dependent cancer and therapy; What is the future of osteoporosis therapy?

November 3, 2015; Hobart, Australia

ANZBMS, MEPSA, MBSANZ Joined Annual Meeting

Title: From rare bone diseases to treatments of osteoporosis: The sclerostin paradigm.

November 14, 2015; Brussels, Belgium

Belgian Society of Orthopedics & Traumatology, Belgian Bone Club

Title: Role of bone metabolism in the pathophysiology of non-union

March 11,12, 2016; Barcelona, Spain

9th Bone Academy

Co-Chair, Speaker

Title: Compare and contrast effects of old and new antiresorptives on bone

April 17, 2016; Malaga, Spain

WCO IOF-ESCEO 2016

Title: Novel targets and therapies for osteoporosis

May 15, 2016; Rome, Italy

ECTS 2016

Title: Inhibition of sclerostin – clinical outcomes

May 31, 2016; Munich, Germany

ECE 2016

Title: New bone forming treatments for osteoporosis

June 11, 2016; London, UK

EULAR 2016

Title: Management of Osteoporosis

October 20, 2016; Genova, Italy
Osteorheumatology 2016
Title: Bisphosphonates in the treatment of Metabolic Bone diseases

November 5, 2016; Ioannina, Greece
24th National Congress EEMMO
Title: New developments in the pharmacotherapy of osteoporosis

November 7, 2016; Brighton, UK
British Society for Endocrinology 2016
Title: Targeting Wnt signaling for the treatment of osteoporosis

November 20, 2016; Geneva, Switzerland
IOF Course-Rare Genetic Disorders of Bone
Title: Too much bone: Bad or Good? General diagnostic strategies for adults with rare skeletal disorders.

November 24, 2016: Amman, Jordan
8th Pan Arab Osteoporosis Society Congress
Title: Challenges in the management of osteoporosis

November 25-27, 2016; Bangkok, Thailand
Bone Academy Asia
Titles: Bone turnover markers: Relationship with bone histology; Comparinig and contrasting antiresorptives: mechanisms of action and clinical benefits; Bone fragility in the young: when to diagnose and treat? Prevention of bone loss in women on aromatase inhibitors: opportunities and challenges

February 10-11, 2017; Vienna, Austria
10th Bone Academy
Co-Chair, Speaker
Title: Sclerostin deficiency: Lessons from human and animal studies

April 29, 2017; Athens, Greece
44th Congress Endocrinology & Diabetes
"Dennis Ikkos" Lecture
Title: Sclerostin deficiency: Lessons from human and animal studies

May 4, 2017; Bern, Switzerland
Swiss Society of Osteoporosis
State of the Art Lecture
Title: Sclerostin: From gene mutations to clinical applications

May 24, 2017; Amsterdam, Netherlands
11th European Congress on Menopause and Andropause
Title: Novel anabolic treatment strategies of postmenopausal osteoporosis

June 10, 2017; Athens, Greece
EUROMEDLAB 2017
Title: New therapeutics for osteoporosis.

September 8, 2017; Denver Co, USA
Annual Meeting ASBMR; Rare Bone Diseases Group
Title: Sclerostin deficiency: Lessons from human studies.

September 29, 2017; Athens, Greece
5th Combo Endocrinology International Course
Title: Subclinical osteoporosis; Should we bother?

October 19, 2017; Genova, Italy
Osteorheumatology 2017
Title: Rare bone diseases: Successes and Challenges

October 26, 2017; Elche, Spain
XXII SEIOMM; Aurelio Rapado Memorial Lecture
Title: Sclerostin: From gene mutations to clinical applications

November 24, 2017; Ljubljana, Slovenia
8th CEE Osteoporosis Summit
Title: Long-term management of osteoporosis

